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Abstract 
 Cancer immunotherapy has advanced rapidly over the past decade leading to clinical 
approval of immune checkpoint blockade and adoptive cell transfer therapies. Further efforts into 
development of therapeutic vaccines had generated promising results in pre-clinical and clinical 
studies. Here, we demonstrate novel methodology for preparation of cell membranes into nano-
sized vesicles and the development of characterization methods via nanoparticle flow cytometry. 
Cancer cell membranes from murine melanoma cell line expressing model antigen, ovalbumin, 
were used for generation of PEGylated vehicles (PEG-NPs), which efficiently delivered 
endogenous membrane-associated cancer antigens to the draining lymph nodes after 
subcutaneous administration. PEG-NPs were efficiently taken up by dendritic cells and, when 
dosed with a potent adjuvant, led to antigen-specific T cell activation and proliferation 
approximately 4-fold greater than treatment with traditional freeze-thaw lysates. In combination 
with immune checkpoint blockade (anti-PD-1 treatment), our vaccination approach led to 
therapeutic cure of 63% of mice and persistent memory responses rejecting additional tumor 
rechallenge. We further utilized our nanoparticle platform by using adjuvant-matured dendritic 
cells (DCs) generating MPLA-activated dendritic cell membrane vesicles ((MPLA)DC-MVs). 
This preparation led to nanoparticles carrying T cell activation ligands (CD80 and CD86) and 
promoted their proliferation activation in vitro compared to antigen peptide alone, as 
demonstrated by 2-fold increase in proliferation and 5- to 8-fold increase in live cell numbers 
and expression of CD25 activation marker. In addition, (MPLA)DC-MVs, but not unstimulated 
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DC-MVs, resulted in activation of immature dendritic cells in vitro, indicated by 2- and 1.3-fold 
greater expression of CD40 and CD80, respectively. Administration of this formulation in vivo 
together with OVA peptide epitope led to 2-fold enhanced expansion and maintenance of 
antigen-specific T cells compared to peptide alone in mice that received adoptive cell transfer or 
had established OVA-expressing tumors. These studies had demonstrated the use for cell 
membranes in immunotherapy as vaccine vehicles, but further characterization and optimization 
could allow for improved efficacy, prompting us to adopt flow cytometry methods aimed at 
nanoparticle analysis. The technique was established by analysis of lipid-based synthetic 
formulations focused on demonstrating effective fluorescence detection and separation of 
individual particle populations. Proof of concept studies were used to confirm presence of 
ovalbumin on membrane-derived vesicles with antibody staining. Finally, we had utilized this 
technique to examine antigen display on hepatitis virus C vaccine formulation in order to 
determine if broadly neutralizing antibodies can bind efficiently and thus if they can be raised in 
mice immunized with these formulations. Our studies demonstrate that similar levels of broadly 
neutralizing antibody binding to nanoparticles translate to similar level of protection against 
cross-strain viral challenge. Taken together, this work has generated a foundation for further 
research into the use of cell membranes as nanoparticles for immunotherapeutic approaches and 
techniques necessary for their characterization. 
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Chapter 1: Introduction 
 
1.1 Melanoma: Current Therapies and Challenges
1
 
Cancer is the second leading cause of death in the United States claiming nearly 600,000 
American lives each year [1]. Over 90,000 Americans with a median age of 60 years old are 
expected to be diagnosed with melanoma in 2018 demonstrating an increase of 15,000 new per 
cases per year since 2014. [1-3]. Approximately 16% of these new cases involve distant 
metastases, which in 2012 have been associated with very poor prognosis with an approximately 
15% 5-year survival rate and resulting in almost 10,000 deaths per year [1, 2]. With the advent of 
newly developed immunotherapies, melanoma prognoses have been becoming more optimistic 
with the expected 5-year survival expected to at least double, if not triple over the next decade, 
while still leaving room for therapeutic improvement and decrease in side effects [4]. 
Melanoma has been linked to prolonged exposure to ultraviolet light and genetic 
predisposition, generally arising as a local lesion which can advance to metastatic disease [5]. 
Early diagnosis of melanoma following surgical resection is associated with good prognosis as 
the cancerous growth can be entirely removed. If left untreated, cancerous cells spread to the 
local lymph nodes and then disseminate throughout the body often establishing metastases in the 
brain, lungs, and liver [5]. For many decades there were only few FDA-approved therapies, 
which can be categorized into three groups: 1) chemotherapy (Dacarbazine), 2) BRAF/MEK 
inhibitors (Dabrafenib, Trametinib, and Vemurafenib), and 3) immune system stimulatory agents 
                                                          
Portions of this chapter have been adapted with permission from Springer Customer Service Centre GmbH: Springer 
Nature, Lipid-Based Nanoparticles for Vaccine Applications by Kuai R*, Ochyl LJ*, Schwendeman A, and Moon JJ 
© 2015 
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(Aldesleukin). Within the past ten years, the field of immunotherapy has undergone tremendous 
progress, leading to the approval of immune checkpoint blockade therapies, which target PD-1 
and CTLA4 (pembrolizumab/nivolumab and ipilimumab, respectively) [6]. 
 Dacarbazine is an alkylating agent used in the clinic for over forty years characterized by 
very low average response rate of 15.3%, mostly comprised of partial responses leading to 
modest progression free survival of 6.4 months [7, 8]. This traditional chemotherapeutic 
approach has recently fallen out of use and has been replaced by more effective targeted and 
immunotherapeutic approaches as described below. Common activating mutation in the V600 
residue of BRAF has been identified in approximately 50% of melanoma cases and has been 
generally associated with poor prognosis [9, 10]. Inhibition of BRAF or MEK in the MAPK 
pathway has been believed to result in an effective therapy for metastatic disease, which has led 
to recent development and FDA approval for three small molecule drugs: vemurafenib, 
dabrafenib, and trametinib [9]. In the most successful trial, combination of dabrafenib and 
trametinib resulted in an increase of the overall response rate to 76% and progression-free 
survival of 9.4 months for patients with the V600 BRAF mutation [11]. Even though these 
kinase inhibitors represent a modern breakthrough in treatment of metastatic melanoma they 
provide modest benefits due to known resistance mechanisms [12]. 
Aside from general chemotherapy and the specific MAPK pathway inhibition, 
immunotherapy has been the only other approach to show efficacy in patients with metastatic 
melanoma. Interleukin-2 (IL-2) has been identified for its anti-tumoral approved for clinical 
trials in very high doses (HD IL-2, under commercial name Aldesleukin) [13]. IL-2 is a potent 
activating T-cell cytokine associated with severe toxicities, which require treatment to be 
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stopped. Analysis of various clinical trials indicates durable complete response rate of 6% and 
partial response rate of 10% leading to 5.9 month progression-free survival [13].  
Ipilimumab is an immunostimulatory agent recently developed for the wide, nonspecific 
activation of T-cell immunity, which acts by blocking inhibitory signaling through a T-cell 
transmembrane receptor CTLA-4 [14]. Recent clinical trials indicate 11% and 15.2% overall 
response when administered as monotherapy or together with dacarbazine, respectively, which is 
comparable to the results obtained using HD IL-2 [14, 15]. Ipilimumab benefits from a markedly 
decreased number of severe side effects, but also does not seem to lead to durable complete 
responses (1.5% and 0.8% for the previously mentioned trials) compared to the HD IL-2 therapy 
(6% complete response) [13-15]. Results from the HD IL-2 and ipilimumab studies provide 
evidence that the immune system can combat cancer, further supported by positive correlation 
between tumor infiltrating lymphocyte counts and survival in patients with melanoma [16].  
Another approach in this area focuses on blocking inhibitory signaling through 
interaction between programmed death 1 (PD-1) receptor expressed by T cells and programmed 
death 1 ligand (PD-1L) expressed in the tumor microenvironment [5]. Two promising 
monoclonal antibodies, pembrolizumab (anti-PD-1) and nivolumab (anti-PD-1L) have 
demonstrated decreased toxicity, increased response rate (between 17% and 44%), and 
comparable frequencies of durable responses as HD IL-2 [17-19]. In fact, response to 
pembrolizumab was not influenced by previous treatment with ipilimumab suggesting that 
synergy may be achieved when targeting these two pathways, which was supported by promising 
results from an early clinical trial consisting of ipilimumab + nivolumab therapy [18, 20]. The 
most recent analysis demonstrates 58% three-year survival, which was unmatched with other 
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approaches, while one third of the patients have shown lack of disease progression during the 
three years hinting at durable, long-term cures [4]. 
However, while immune checkpoint inhibition is considered generally safe, high grade 
toxicities may occur during treatment, with the loosened reins on the immune system. Generally, 
decreasing the dose or abandoning therapy allows the side effects to subside, but the therapeutic 
efficacy may be lost. It is important to remember the purpose of immune checkpoints, where in 
healthy adults they prevent of autoimmune disease and excessive tissue damage during 
inflammation [21]. As these biologic drugs make their way through the clinic, monitoring and 
analysis of long term effects is necessary as demonstrated recently by evidence of cardiotoxicity 
following CTLA4 and PD-1 therapy [22]. Treatment protocols are currently being optimized, 
thus establishing efficacious and safe therapies – however, due to this delicate balance, other 
treatment modalities may be needed to provide the necessary improvements. 
While many advances have been made, the currently available therapies for metastatic 
melanoma had demonstrated either low levels of response or short duration. In addition, the 
MAPK pathway inhibitors are generally well tolerated but resistance rapidly develops resulting 
in small benefit to overall survival. BRAF inhibitors were successful because of their high level 
of specificity, whereas immunotherapies exploited the specificity of the body’s own immune 
system, but were effective in only a small fraction of patients. It appears that not only activation, 
but also guidance of the immune system may be necessary to achieve durable responses in 
majority of patients, which has led to attempts to develop therapeutic cancer vaccines explored 
below. 
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1.2 Introduction to the Immune System 
 The immune system has developed to protect the host from a variety of pathogens such as 
bacteria and viruses. It can be divided into two branches of innate and adaptive immunity. The 
former plays an important role in eradication and/or containment of infectious pathogens at an 
early stage. Innate immunity relies on common and evolutionarily preserved elements of viruses 
and bacteria known as pathogen-associated molecular patterns (PAMPs) for recognition using 
pathogen recognition receptors (PRRs) [23]. This early response provides time for the adaptive 
immunity to form, where antigen presenting cells (APCs) sample pathogens for immunogenic 
antigens and present them to the effector cells of the adaptive immunity (T and B cells), giving 
rise to a specific and effective response. This process has also been recognized to identify and 
kill abnormal cells with tumorigenic properties, supported by increased incidence rates of cancer 
among immunocompromised populations [24]. 
1.2.1 Antigen Presentation 
 Antigen presenting cells (APCs) bridge innate and adaptive immunity by capturing 
pathogens and delivering antigens to the effector T and B cells. Relatively recently recognized 
dendritic cells (DCs) play a major role in this process and have been termed professional APCs. 
DCs function by continually sampling their environment and preferentially recognizing 
pathogens through the action of PRRs in a similar way to macrophages [25]. However, rather 
than upregulating phagocytic behavior and trafficking pathogens to lysosomes for degradation, 
DCs process and conserve antigens and begin their migration to the local lymph node [26]. Once 
there, antigens are presented on the cell surface along with an array of stimulatory 
transmembrane proteins in order to activate antigen-specific T cells. In particular, certain DC 
subsets possess a unique ability of cross-presentation, a process involving presentation of 
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extracellular antigens on major histocompatibility complex class I (MHC-I), strictly necessary 
for cytotoxic T cell response [27].  
 MHC-I is expressed by every cell in the body and in a traditional antigen-presentation 
pathway functions as a surveillance mechanism for viral and intracellular infections [28]. Cells 
continuously turn over cytosolic proteins through the action of proteasome, which cleaves them 
into short amino acid chains. These peptides are then transported into the endoplasmic reticulum 
(ER) via TAP1/2, where they bind to MHC-I producing unique peptide-MHC-I complexes, 
which are then trafficked to the plasma membrane, allowing healthy cells to present self-antigens 
on their surface [29]. Infected cells contain bacterial or viral proteins, which are processed in the 
exact same way, leading to foreign antigen display on the plasma membrane. These cells are then 
readily recognized and killed by antigen-specific cytotoxic T lymphocytes. 
 Normal cells fail to express immunostimulatory molecules such as CD80/86 to activate 
and expand the antigen-specific CTL clone, thus for the traditional antigen-presentation pathway 
to  work, APCs would have to be infected directly, which may be a rare and unreliable event. 
Because of this, a process of cross-presentation has evolved, where APCs can take up antigens 
from the extracellular space and present them on MHC-I [27]. This complex and still not fully 
understood process involves antigen capture and trafficking into endosomes, which can briefly 
fuse with the ER and extract the necessary machinery for cross-presentation. Proteins can then be 
degraded directly by endosomal proteases and loaded onto MHC-I, which is known as the 
vacuolar pathway, or they can be translocated into the cytoplasm with the assistance of Sec61 
protein, degraded by the proteasome, and trafficked back via TAP1/2 complex to be loaded onto 
MHC-I [27]. 
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 Cross-presentation often occurs due to the naturally occurring cues, such as TLR 
signaling. It is also very difficult to induce artificially and has been the major challenge in 
eliciting CTL responses. A few strategies have been employed to circumvent this issue by 
disrupting the endosomal membrane and thus allowing the antigens to enter the cytosol. One of 
these approaches involves conjugation of fusogenic or cell-penetrating peptides to the surface of 
nanoparticles. These peptides are generally composed of positively charged amino acids and can 
adsorb and disrupt the negatively charged lipid bilayer. In one particular case, OVA-loaded 
liposomes were modified with octaarganine (R8) leading to 5- and 55-fold increase in OVA 
presentation on MHC-I compared to cationic liposomes and soluble OVA, respectively [30]. 
Another strategy employed conjugation of pH-dependent fusogenic polymer (linear 3-
methylglutarylated poly(glycidol)) to liposomal surface and induced high OVA delivery to the 
cytosol, thus increasing CTL responses and providing protective immunity against challenges 
with OVA-expressing murine lymphoma model and retarding growth of established tumors [31]. 
Other approaches involve biomimetic incorporation of listeriolysin O, a pathogenic element 
which induces endosomal lysis in response to decreasing pH, leading to increased cytosolic 
delivery of OVA and significantly higher cross-presentation efficiency [32]. In the end, more 
advanced strategies for successful antigen delivery to dendritic cells and stimulation of pathways 
involved in surface peptide-MHC-I display are necessary to achieve strong anti-tumor CTL 
responses. 
1.2.2 Cytotoxic T Lymphocyte Response 
 CD8
+
 T cells or cytotoxic T lymphocytes (CTLs) are very important for combating 
intracellular infection as well as cancer. During CD8
+
 T cell development in the thymus, the T-
cell receptor (TCR) gene undergoes recombination in order to create unique antigen binding sites 
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[33]. TCRs are then exposed to MHC-I-self-peptide complexes presented by thymus-resident 
cells; if the binding is too weak, cells undergo apoptosis as their TCR cannot functionally bind to 
MHC-I, but if the binding is too strong, there’s a potential for autoimmunity and those cells are 
deleted as well. Thus only T cells with intermediate affinity for self-peptides develop fully, 
which makes cancer immunotherapy directed at tumor associated antigens difficult, as the high 
affinity clones are eliminated in the process. 
 Following development, naïve T cells circulate throughout the body, traveling to lymph 
nodes and various tissues, where they can become activated. In order to fully promote T cell 
expansion, three different signaling events must take place [34]. Signal 1 is delivered through the 
interaction of TCR and MHC-I-peptide complex presented on APCs. Signal 2 comes from CD28 
expressed on T cells and its binding to CD80 or CD86, which is expressed on mature and fully 
activated dendritic cells. Once sufficient activation occurs, T cells upregulate another surface 
receptor, CTLA4, which binds to CD80 and CD86 with a much higher affinity than CD28 and 
leads to inhibitory signaling. This mechanism serves to stop uncontrollable T cell expansion after 
activation and has been a target to increase immunogenicity with the use of CTLA4-specific 
monoclonal antibodies [14]. Finally, IL-2 produced by CD4
+
 T cells or CD8
+
 T cells themselves 
is necessary for functional development of CTLs and is considered to be Signal 3. 
 Once T cells are activated they can travel to sites of inflammation following cytokine 
gradients and seek out their targets by screening MHC-I-peptide complexes expressed on cell 
surfaces. Following recognition of the specific antigen, CTLs secrete granzymes and perforins 
which can effectively lyse the plasma membrane of target cells and induce signal transduction 
cascade leading to apoptosis [28]. After stimulation with IFNγ, healthy cells at the sites of 
inflammation upregulate Programmed Death Ligand 1 (PD-L1), which can bind to Programmed 
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Death 1 (PD-1) receptor on T-cells and induce their apoptosis [35]. This mechanism is necessary 
to prevent overly active immune response and prevent damage to the healthy tissue. 
Unfortunately, many tumors have hi-jacked this approach and create a severely 
immunosuppressive environment where CTLs cannot function properly. This interaction has 
been a target of recently developed monoclonal antibodies, which show efficacy as 
monotherapies, but may have an even greater impact when combined with cancer vaccines.  
Although direct activation of CD8
+
 T cells by APCs is considered to play the central role 
in anti-tumoral immune response, T helper (Th), or CD4
+
, cells are also of particular importance. 
Aside from assisting with humoral responses, they are responsible for secretion of IL-2 necessary 
for effective CD8
+
 T cell proliferation and IFNγ, which enhances maturation and functionality of 
dendritic cells [36]. In addition, Th cells also transiently express CD40L, which feeds back to 
DCs leading to further activation and upregulation of costimulatory factors and cytokines such as 
IL-12, necessary for functional CTL development and prolonged action at the site of the tumor 
[37, 38]. Finally, Th cells play a substantial role in eliciting memory phenotype, which allows for 
CTL persistence and thus increased efficacy against metastases and relapse [37]. There are a few 
differentiation paths that Th cells can take including Th1 and Th2 phenotype most commonly 
elicited by vaccines, which favor CTL and humoral responses respectively. Thus, it is important 
for cancer vaccine formulations to induce the Th1 response as it would aid CTLs most 
effectively. The advantage of subunit and whole tumor cell lysate over peptide vaccination is 
also evident here, considering that epitopes for MHC-I and MHC-II would be present thus 
allowing for direct activation of CTL and Th responses. 
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1.3 Vaccine Components 
 Vaccination has been claimed as the most effective form of preventative medicine in 
decreasing healthcare costs, human suffering, and death. Development of cancer vaccination has 
begun in early 1990s, aimed at the use of peptides and whole tumor cell lysates, and despite 
significant advancements still faces major challenges [39]. Many factors can influence vaccine 
efficacy including site of the injection and timing of the primary and booster immunizations. 
However, the vaccine composition has a predominant effect on the type and strength of 
immunity which can be achieved. Antigens are generally fragments of proteins which can be 
recognized by the effector component of the immune system. In addition, the immune action 
against that antigen must be triggered, thus there must be an activating component associated 
with every vaccine, which can range from emulsifying of the antigen to inclusion of various 
immunostimulatory molecules (adjuvants). 
1.3.1 Antigens 
 Melanoma-specific proteins involved in melanin production have been identified as 
potential vaccine targets and include glycoprotein 100 (gp100), Melan-A/MART-1, and 
tyrosinase [40]. Other potential targets include common tumor-restricted antigens such as 
MART-2, MAGE-1, MAGE-3 and NY-ESO-1. Peptide vaccinations may prove more efficacious 
due to their effective dose at delivery and lack of necessity for cross-presentation. In addition, 
due to the differences between the protein cleavage properties of cellular proteasome and the 
DC-expressed immunoproteasome, effective immunity against a particular epitope may not 
always be achieved with the use of whole protein vaccination and peptides may need to be 
employed (e.g. melanoma-associated MART 1 immunogenic epitope failed to be presented on 
MHC-I in DCs transduced to express the protein in the cytosol) [41]. Problems stemming from 
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the localization of peptides in vivo prevent direct administration and require nanoparticle 
formulations or emulsification agents.  
Administration of gp100 immunogenic peptide emulsified in Montanide ISA-51 together 
with Interleukin-2 led to increased response rate (20% vs 10%) and greater median overall 
survival (17.8 vs 11.1 months) compared to the IL-2 only treatment [42]. Immunization with 
gp100 together with ipilimumab did not improve efficacy over ipilimumab treatment alone, 
presenting the complexity of the cancer vaccination challenge, but can also be explained by the 
heterogeneity of most tumors and insufficient immune response [14].  Administration of 
dendritic cells pulsed ex vivo with five immunogenic peptides derived from melanoma tumor 
proteins (gp100, tyrosinase, MAGE-A2, MAGE-A3, and MART-1) demonstrated improved 
overall survival [43]. Other approaches aimed at eliciting multivalent responses focused on 
tumor cell lysate administration tested in multiple clinical trials, but were met with low response 
rates and insufficient benefits [40]. These issues may be explained by lack of immunogenicity of 
tumor cell lysates and low cross-presentation efficiency, which are currently being addressed 
with the use of various adjuvants and nanoparticle formulations.  
Aside from development of the immune checkpoint blockade over the past decade, there 
has been a major shift in the antigens targeted by today’s vaccines. The focus has gone away 
from poorly immunogenic self-antigens, which have had limited efficacy and continuous 
concerns about potential autoimmunity, but rather, due to the highly mutagenic cancer genome 
(resulting from diminished capabilities of DNA repair and resistance to apoptosis), fell on a new 
class of epitopes [44]. Often, as a result of single point mutation or shift in the reading frame, the 
primary amino acid structure will be affected leading to generation of a new sequence. This may 
lead to a new epitope, termed neo-antigen, which may be immunogenic due to enhanced cellular 
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processing, MHC-I binding affinity, or T cell receptor recognition. The past five years have 
shown translation from initial mouse studies focusing on identification of neo-antigens in cell 
lines and showing efficacy in pre-clinical studies [45, 46] to the first reports of human trials 
demonstrating complete and durable cures [47, 48]. There is no doubt that this approach has 
tremendous promise in the future of cancer immunotherapy, prompting extensive research in 
formulation and delivery of neo-antigen vaccines [49]. 
1.3.2 Adjuvants 
Cancer therapeutic vaccines struggle with poorly immunogenic antigens and lack of 
proper adjuvants for induction of cross-presentation and strong CTL responses [50]. Current 
clinically-used adjuvants include aluminum salts (Alum) and squalene-based oil-in-water 
emulsions (MF59 and AS03), which induce inflammatory responses and thus recruit APCs to the 
site of the injection allowing antigen sampling, providing immunogenic cues, and most 
commonly resulting in increased humoral responses [51]. Additionally, receptors involved in 
recognition of pathogen associated molecular patterns (PAMPs) have been identified as key 
players in APC activation and include primarily studied Toll-like receptors (TLRs), as well as 
less understood nucleotide-binding domain (NOD) receptors, NOD-like receptors (NLRs), RIG-
1-like receptors, integrins and C-type lectins. The latter receptors have been receiving increasing 
amounts of attention lately, but it is the better-understood TLR agonists that have made it into 
the clinic thus far. 
Double stranded RNA (dsRNA) associated with viral infections activates TLR3 in the 
endosomal compartment and promotes Th1-skewed responses, which favor involvement of 
CTLs [50]. Additionally, dsRNA molecules such as synthetic polyinosinic:cytidylic acid  
(polyI:C) can also activate cytosolic receptors such as retinoic acid-inducible gene-1(RIG-I) and 
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melanoma differentiation associated gene 5 (MDA5), which together with TLR3 signaling may 
induce synergistic effects and induce increased IL-12 and type I interferon (IFN) secretion. 
PolyI:C can be administered in a complex with poly-L-lysine in order to increase stability and 
counter the highly negative charge, thus allowing for effective topical administration currently 
showing safety and efficacy in clinical trials against glioblastoma [52]. Additionally, polyI:C can 
be freely administered as a soluble adjuvant along with nanoparticle formulations via 
intratracheal route in order to boost mucosal CTL responses [53]. Finally, co-loading of OVA 
and polyI:C into fusogenic liposomes led to superior anti-tumoral effects compared to OVA-
polyI:C complexes, thus suggesting that cytosolic delivery of the dsRNA may induce MDA5-
mediated signaling and improved efficacy, although this causality was not tested by the authors 
[54]. 
TLR4 has been identified for its role in recognition of lipopolysaccharide (LPS) and 
induction of adaptive immunity [55]. Non-pyrogenic LPS analog, monophosphoryl lipid A 
(MPLA) is associated with Th1-skewed response and has been FDA approved for use in 
Cervarix and Fendrix, aluminum-salt-based vaccines against human papilloma virus (HPV) and 
hepatitis B virus (HBV), respectively [51]. Lipid-based particles provide an additional advantage 
in delivery of MPLA at dose-sparing amounts, as it can partition effectively into the hydrophobic 
membrane. Efficacy of TLR signaling was demonstrated by increased upregulation of splenic 
DC maturation markers, when cells were co-cultured with MPLA-containing particles compared 
to adjuvant free formulation, and induction of high levels of antigen-specific CTL response in 
vivo [56].  
 TLR7 and TLR8 expressed in the endosomal compartment are responsible for detection 
of single stranded RNA (ssRNA) rich in guanosine and uridine [50]. Considering that RNA is 
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inherently unstable, small molecule compounds capable of activating TLR7 (Imiquimod) and 
TLR7/8 (Resiquimod or R848) were developed, which do not show efficacy when administered 
as a soluble vaccine, possibly due to high hydrophobicity, thus strongly affecting their co-
localization with the antigen. Approaches involving conjugation of these agonists to antigens and 
nanoparticle formulation have been used in order to achieve responses. Due to high permeability, 
Imiquimod has also been used as a 5% cream for topical administration at tumor sites in various 
benign skin neoplasms, but also as experimental immunotherapy for melanoma patients which 
has shown increased T cell activation alone, and together with CpG/Melan A peptide 
vaccination, promoted strong antigen-specific central memory phenotype CTL responses  [57, 
58]. 
Human DNA contains methylated CpG motifs which are not present in bacteria and 
viruses, thus providing a marker for pathogenic DNA recognized by TLR9 [50]. TLR9 is not 
expressed in human myeloid DCs, known for their superior cross-presentation efficiency, but 
activation of TLR9 in plasmacytoid DCs is believed to promote high level of IFNγ production 
responsible for antibody responses, promotion of T cell proliferation, survival and memory 
phenotype, as well as strong polarization of the T helper cell phenotype to CTL-supportive Th1 
[59]. CpG has been used in various cancer therapeutic vaccine approaches and has most made it 
into clinical trials incorporated into water-in-oil emulsion (Montanide) together with 
immunogenic peptide from melanoma-specific protein, Melan-A [60]. It has also been 
extensively explored as an adjuvant for numerous vaccine approaches intended for various 
cancers and infectious diseases demonstrating relatively safety when given at lower doses [61]. 
 TLR3 and some TLR4 signaling relies strongly on TRIF adaptor molecule and leads to 
activation of type I IFN production, whereas remaining TLRs signal through Myd88 associated 
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with activation of NF-κB transcription factor. These signaling cascades as well activation of the 
two different transcription factors have been shown to elicit synergistic effects and are associated 
with stronger and broader immune responses [51]. In particular, simple intraperitoneal 
administration of CpG and PolyI:C together led to increased levels of cytokine production 
including IL-12 and enhanced anti-tumoral response against established melanoma lung 
metastases compared to either adjuvant alone [62]. Overall, it is difficult to predict which 
combinations will work and generally must be tested on a case by case basis, thus providing 
opportunities for development of multiadjuvant therapies. 
 
1.4 Immunotherapies in Development 
  Currently approved immunotherapeutic agents, HD IL-2 and checkpoint blockade 
inhibitors, act systemically by nonspecific activation of T-cell immunity leading to low response 
rate, but produce durable effects making immunotherapy a very promising field. Directing the 
immune response toward anti-tumor responses via vaccination has been suggested for decades, 
but quite difficult to achieve, due to central tolerance and lack of visible objective responses, 
often associated with the “adaptive resistance” [21]. Due to the immune infiltration and 
inflammation, local production of IFNγ fuels upregulation of PD-1L on tumors cells, which in 
turn decreases T cell function and promotes immunosuppressive environment. Introduction and 
development of immune checkpoint blockade allowed for vaccine-mediated tumor antigen-
specific T cell expansion to kill tumor cells efficiency and without any hindrance, which led to 
extensive progress in tumor vaccine development. 
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1.4.1 Dendritic-cell-based Therapies  
 Provenge is the only cancer vaccine currently approved by the FDA and is associated 
with a 4.1 month increase in median overall survival of patients with advanced prostate cancer 
[63]. Cancer therapeutic vaccinations involve presentation of tumor associated antigens (TAAs) 
in an immunogenic setting to induce anti-tumoral responses, but so far the results have been 
limited and disappointing [39]. Current methods of TAA delivery vary and generally include 
pulsing ex vivo cultured DCs with tumor cell lysates or peptide antigens, which have been the 
only therapies associated with notable responses [39, 64, 65]. Dendritic cell vaccinations have 
been explored for nearly two decades following discovery and verification of these professional 
antigen presenting cells (APCs) and led to hundreds of DC-based vaccines in clinical trials 
across the United States [66].  Unfortunately, even though promising results have been observed 
since the late 1990s, most therapies fail to elicit sufficient response ultimately preventing further 
development.  
A phase II clinical trial, in which ex vivo cultured DCs were pulsed with a cocktail 
containing five melanoma peptide antigens (gp100, tyrosinase, MAGE-A2, MAGE-A3, and 
MART-1), has shown significant improvement in overall survival of patients from 7.3 to 13.6 
months [43]. In addition, outcome was strongly correlated to the level of immune response as 
determined by an ELISPOT assay, and the overall survival for high-responding patients was 21.9 
months compared to 8.1 months in low-responding patients. Another phase II clinical trial 
focused on DC-based vaccination using irradiated autologous tumor cells with self-renewing and 
proliferative characteristics (indicative of the CSC populations) and resulted in a five-year 
survival rate of 54% [67]. In a comparative study DC-vaccinated patients achieved two-year 
survival rate of 72% compared to 31% in patients who only received irradiated tumor cells [68]. 
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These promising results led to a promising launch of a large scale phase III clinical trial for 
melanoma (NCT01875653). 
Dendritic cells are generated from ex vivo cultured monocytes or CD34
+
 progenitor cells 
obtained from patients’ peripheral blood, although recent reports indicate that these artificial 
DCs may not be as effective as naturally occurring plasmacytoid dendritic cells, thus recognizing 
an area for future progress [69]. Utilization of dendritic cells has shown clinical efficacy, but 
involves labor-intensive and expensive methods, such as FDA-approved Provenge dendritic cell 
vaccine, which requires a four day process at cGMP (current good manufacturing practice) 
facilities and costs $93,000 per therapy [70]. It is not surprising that a lot of different therapies 
and approaches are being studied, but due to young age and significant challenges in the field, 
have not yet made the transition to the bedside just yet. Overall, cancer immunotherapy has 
become a very attractive field in the recent years, as it employs very specific and often durable 
responses compared to treatments with toxic chemotherapy or small molecule inhibitors often 
associated with resistance mechanisms. 
1.4.2 Pre-clinical Whole Tumor Cell Therapies 
 Importance of CTL responses in cancer immunotherapy has prompted numerous studies 
focused on cytosolic delivery of tumor associated antigens and promoting their immunogenicity. 
Several murine cancer models (i.e. B16 melanoma and EL4 lymphoma) have been developed in 
order to aid with research in immunocompetent animals. In addition, these cell lines have been 
transduced with stable expression of ovalbumin (OVA), providing important models for studying 
immunogenic delivery of this model antigen. Granted that generation of an immune response 
with the aid of an exogenous antigen is less challenging, these results need to be examined 
carefully and reevaluated with the use of tumor associated self-antigens.   
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 Advantages of using whole tumor cell antigen repertoire include multivalent responses as 
well as idea of personalized medicine, but the approach has not been very successful thus far. 
Studies aiming at inducing immune responses include incorporation of whole tumor cell lysates 
into particle formulations, which can benefit ex vivo pulsed DCs by eliciting superior level of 
cross-presentation [71]. These benefits were extended by direct immunization with fusogenic 
liposomes encapsulated with B16BL6 lysates, which decreased tumor growth in mice [72]. In 
addition, encapsulation of E.G7 into PLGA microspheres with CpG and PolyI:C and in vivo 
administration, led to expansion of E.G7-specific and functional CTLs and regression of 
established subcutaneous tumors in mice [73].  
Administration of inactivated tumor cells is also explored as the in vivo immunogenic 
tumor cell death is believed to promote anti-tumoral responses.  A recent study focused on 
nanoparticle-induced loading of IL-2 and GM-CSF into irradiated Lewis lung carcinoma (LLC) 
tumor cells followed by subcutaneous administration [74]. Together with the immunogenic death 
of the cells, the controlled release of cytokines, which can attract DCs, led to improved 
infiltration of CTLs into the tumor site, prophylactic and therapeutic responses in tumor models, 
and decreased metastatic behavior of established tumors. 
Other approaches involve implantation of antigen and adjuvant co-loaded scaffolds. A 
recent study used poly(D,L-lactide-co-glycolide) (PLG) matrices co-loaded with tumor cell 
lysates obtained from digested primary tumors, DC-activation granulocyte macrophage colony-
stimulating factor (GM-CSF), and three different TLR agonists: PolyI:C, MPLA, and CpG [75]. 
The findings indicted that PolyI:C and CpG prolonged stimulation and homing of dendritic cells 
to the local lymph nodes which correlated with improved therapeutic responses (tumor volume 
and overall survival) in mice with established tumors compared to the use MPLA. In addition, 
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using a knock-out model, it was demonstrated that CD8
+
 DCs, known for their role in cross-
presentation, are necessary for induction of effective CTL response. IL-12 and granulocyte 
colony-stimulating factor (G-CSF) production correlated positively with anti-tumoral response, 
thus providing potential biomarkers for future studies. Finally, feasibility of immunization using 
whole tumor cell lysates from a primary source sample was demonstrated. 
 Focus of current studies includes enhancing cross-presentation of tumor associated 
antigens as well as promoting Th1-skewed cytokine responses. Approaches using tumor cell 
lysates as the source of antigens have been shown to elicit responses in the laboratory, although a 
lot of improvement is still needed as no therapies achieved objective responses in clinical studies 
[40]. Important questions currently being investigated involve the vehicle and the combination of 
adjuvant needed to elicit a potent CTL response. 
 
1.5 Nanoparticle Delivery Systems 
 Induction of an effective response against self-antigens is difficult and requires the use of 
adjuvants to provide immunostimulatory cues as described above. Simple mixing of the adjuvant 
and the antigen prior to administration is also insufficient due to many reasons. For example, the 
antigen can be degraded prior to being taken up by an antigen presenting cell (APC) or it can be 
taken up separately from the adjuvant, thus inducing a tolerogenic response [76].  
Nanoparticle formulations have been used successfully in the past for vaccination, as they 
effectively increase antigen delivery to APCs. This occurs due to endocytosis-inducing size and 
shape of the particles, which mimic characteristics of pathogens. Additionally, particle size and 
charge may strongly affect biodistribution and retention time of the particles in lymph nodes and 
spleens, thus enhancing exposure to APCs and affecting the type and level of response [77-79]. 
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Another major benefit of nanoparticle systems includes co-loading of the antigen with an 
adjuvant, thus delivering both components to the same dendritic cell, which are necessary for 
Signal 1 and 2 for T-cell activation [76, 80]. These effects were supported by numerous studies 
and in particular demonstrated by increased CTL responses elicited by delivery of PolyI:C 
encapsulated within fusogenic liposomes compared to fusogenic liposomes administered 
together with soluble PolyI:C [54]. 
In addition, nanoparticles can effectively protect their cargo from degradation in serum 
conditions and can effectively traffic through the lymphatic making them ideal for in vivo 
antigen delivery thus offering an alternative to labor-intensive and expensive cell-based 
therapies. Targeting of the antigens to the cytosol of APCs can also be enhanced by variety of 
nanoparticle systems exhibiting endosomal escape characteristics, thus allowing for effective 
antigen cross-presentation and induction of CTL responses, which generally fail to be developed 
by traditional vaccination methods. 
These systems generally do not induce immune responses against the vehicle itself due to 
lack of protein components. This allows for multiple administrations of the same formulation 
without induction of an immune reaction or loss of potency, providing advantage over viral 
vectors. Additionally, polyethylene glycol can be incorporated on particle surface leading to 
decreased aggregation, increased lymph node accumulation, and prolonging antigen exposure 
due to ease with which nanoparticle surfaces can be functionalized [81]. These also provide 
potential for enhancing delivery to specific cells (e.g. APCs) by conjugation of receptor ligands 
or antibodies [82]. 
Nanoparticles can be composed of variety of materials ranging from metals and synthetic 
polymers to natural polymers and lipid-based systems, thus their characteristics can be finely 
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tuned, although risks and benefits must be carefully weighed. In particular, lipid-based 
nanoparticles offer advantages in material biocompatibility and biodegradability making them 
safe for use and preventing accumulation in the body [83]. On the other hand, these lipid-based 
platforms are prone to degradation and early antigen release, which has been a major difficulty 
and focus of many current studies. As described below, variety of nature-inspired carrier systems 
and vaccine approaches have also been studied recently including the use of cell membranes for 
antigen delivery.  
 Plasma cell membranes, very complex structures composing of lipids and proteins, serve 
many critical cell functions. Recent focus has shifted onto the generation of exosomes and 
microvesicles, which can bud off from the cell surface [84, 85]. While these vesicles are 
continuously produced and shed by cells, they can carry proteins or even RNA molecules 
promoting cell-to-cell communication. There has been extensive interest in use of red blood cell 
enucleated “ghosts” for use in drug delivery due to their biodistribution profiles and prolonged 
half-life. In addition, cell membranes derived from various cell subtypes display surface markers, 
ligands, or enzymes with very specific function thus prompting their development and use [86-
88]. 
 The membrane preparation technology and utilization developed through these studies 
allowed for the focus on tumor cell membranes and their role in cancer therapies. In particular, 
utilization of sonicated melanoma cell membranes in combination with encapsulated CpG has 
resulted in the generation of the therapy termed “reduced cancer cell” (RCC) vaccine [89]. This 
strategy was characterized using in vitro models of T cell responses and demonstrated limited T 
cell activation in vivo. Others focused on PLGA particles loaded with CpG and cloaking them 
with melanoma membranes to demonstrate effective localization to the draining lymph nodes 
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displaying detectable level of prophylactic and therapeutic efficacy [90]. Taken together, these 
studies demonstrate interest in tumor cell membrane-based cancer immunotherapy approaches 
due to their nanoparticle advantages such as biocompatibility, size-dependent lymph node 
draining, and prolonged stability. However, limited successes of these studies call for further 
research. In particular, PEGylation of cancer cell membranes may aid in their ability to 
effectively traffic to the lymph nodes, while loading of peptides onto immunogenic cell 
membranes may promote effective antigen-specific responses. 
  Improvements for nanoparticle-based therapies require effective characterization prior to 
pre-clinical studies in order to provide efficient throughput for approach validation. Currently, 
formulations are examined for physiochemical characteristics and cargo loading prior to 
empirical pre-clinical animal studies. Particle size and surface characteristics have been 
correlated to their ability to efficiently drain to the local lymph, providing a set of guidelines 
needed for optimal formulations. However, while the encapsulation amount is necessary for 
appropriate antigen dosing in immunotherapies, it may not always convert to administration of 
immunologically active molecules [91]. There is a need for high-throughput technique, which 
can predict the immunogenic efficiency of nanoparticles displaying antigens on their surface. 
Flow cytometry approaches have been utilized for assessment of cellular exosomes and 
microvesicles, providing an opportunity to exploit this approach for use with nanoparticle 
vaccine formulations. 
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1.6 Conclusions 
 Melanoma affects hundreds of thousands of patients every year in the United States, and 
disease progression to the metastatic grade used to be associated with extremely poor prognosis. 
Through the introduction of immune checkpoint blockade, the landscape has shifted greatly, 
resulting in two- to three-fold increase in 5-year survival rate. It has also allowed for new and 
promising approaches to be further explored and promoted further investigation into neo-antigen 
vaccination, which has demonstrated tremendous curative capabilities in small-scale clinical 
trials. As it stands, the outlook on the future is extremely positive, although details must be 
worked out in order to establish efficacious protocols which also limit short- and long-term 
safety concerns.  
Since melanoma is responsible for less than 2% of cancer deaths in the United States, 
adapting these approaches to other tumor types is imperative and these efforts have been 
underway. In fact, it is no coincidence that immunotherapeutic approaches pioneered combating 
melanoma. Due to extensive time necessary for disease progression, uniqueness of melanocytes, 
and commonly dysfunctional DNA repair mechanism, melanoma has been characterized by the 
most extensive mutational burden [92]. This has been regarded as the reason for high number of 
tumor-infiltrating lymphocytes and responsiveness towards immune therapies. Further work is 
necessary in order to adapt these approaches for use against less immunogenic tumor types. 
While tremendous progress has been made with the use of immunotherapies, future approaches 
are likely to focus on nanoparticle- and membrane-based vaccination to harness their ability to 
elicit strong responses while limiting adverse effects. 
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1.7 Motivation 
 The heterogeneity of cancer across tissues, classifications, persons, and even individual 
metastases of the same patient has become evident and calls for highly personalized approaches. 
Recent studies have focused on next generation sequencing in order to identify patient-specific 
neo-antigens or tumor-reactive T/B cell receptors, allowing for generation of novel vaccine 
systems and cell engineering approaches. However, while extremely promising, the cost and 
time-to-treatment of these therapies is high at this moment, thus alternatives must be explored. 
The above-mentioned sequencing requires tissue biopsy or tumor resection, which provides 
cellular material that in turn can be used to develop an effective vaccine. Our approach has 
focused on utilization of the available tumor tissue in order to generate nano-sized tumor cell 
membrane vesicles. The composition of the vehicle would consist of endogenous plasma 
membrane and tumor proteins (both self- and tumor-specific antigens), allowing for minimal 
vehicle-directed immunity, focus on enhancing responses against cancer, and complete 
biocompatibility and biodegradability. In addition, stabilizing surface modification and potent 
immunostimulatory molecules would be included in order to provide efficient lymph node 
delivery and immune activation. This approach demonstrates facile production of vaccines that 
can be administered without prolonged turnaround time allowing for recruitment of the immune 
system to fight against cancer as early as possible.   
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Chapter 2: PEGylated Cancer Cell Membranes for Elicitation of Anti-tumor Cytotoxic T 
Lymphocyte Responses 
 
2.1 Abstract 
Immunotherapy has become a very promising approach against cancer with the clinical 
approval of immune checkpoint blockade, while vaccination efforts have led to improved anti-
tumor responses in clinical trials. In this study, we sought to establish an autologous cancer 
vaccine utilizing tumor cells for development of antigen and adjuvant delivery vehicle. Cell 
membranes can be harvested from tissue-culture grown cancer cells, PEGylated. and formed into 
nano-sized vesicles (PEG-NPs) allowing for enhanced stability and improved draining efficiency 
to the local lymph nodes. We demonstrate the advantages of this formulation in eliciting 3.7-fold 
greater cytotoxic T lymphocyte responses against model antigen, OVA, compared to standard 
freeze-thawed lysates in a therapeutic vaccination against B16F10 OVA melanoma, leading to 
decreased tumor growth. Importantly, in combination with αPD-1 therapy, PEG-NPs led to 4.2-
fold improved T cell responses, decreased tumor growth, and complete tumor regression in 63% 
of mice, which were further protected from a subsequent tumor rechallenge. These results 
support previous effort demonstrating that cancer cell membranes can be used as a vaccination 
platform and elicit strong anti-tumor responses. 
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2.2 Introduction 
Cancer is a continually increasing concern facing the aging population and the rising 
incidence of melanoma of the skin leads to nearly 100,000 new cases and over 9,000 deaths per 
year in the US [1]. The immunotherapy breakthroughs over the past decade have recognized the 
previously suggested role of the immune system in fighting cancer, leading to the clinical 
approval of checkpoint blockade inhibitors including αCTLA4 and αPD-1 antibodies [2-6]. 
While tumor regression and complete cures have been seen with these approaches in many 
patients, the limited response rate to immune checkpoint blockade demonstrate the need for new 
approaches [7]. 
 One of the drawbacks of PD-1 targeting is the reliance on patients’ endogenous tumor-
specific cytotoxic T lymphocyte (CTL) responses, which may be low or absent [8]. Therapeutic 
vaccination may address this issue by eliciting CTL responses, but current cancer vaccine 
approaches require identification and manufacturing of tumor antigens [9, 10]. Specifically, 
following tumor exome sequencing, promising peptide-based neo-antigen vaccines can deliver 
large doses of immunogenic epitopes resulting in strong and durable levels of responses [11, 12]. 
In comparison tumor cell lysates, containing complete library of self- and tumor-associated 
antigens, are readily available for processing and vaccine generation without the need for 
sequencing or peptide synthesis [13]. However, the use of lysates remains challenging because of 
the limited antigen dose, which can be realistically obtained, thus potent formulations containing 
strong immunostimulatory adjuvants must be prepared. 
In the past, tumor cell lysates have been utilized by incorporation into nanoparticle 
preparations or administration as ex vivo generated dendritic cell-based vaccines, but their 
efficacy has been quite limited [14-17]. Recently, advances in plasma membrane utilization and 
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preparation technology yielded impressive results demonstrating in vivo stability and targeting 
[18-20], all the while exosomes and plasma membrane microvesicles were being identified as 
signaling messengers capable of carrying variety of cargos [21-23]. As a result, reports have 
shown that membrane vesicles formulated with adjuvants can be used effectively for eliciting 
immune responses against melanoma, although the therapeutic outcomes have been limited [24, 
25]. 
 In this study, we demonstrate a simple method for generation of nano-sized membrane 
vesicles from B16F10 OVA melanoma cell lysates, which can elicit strong tumor antigen-
specific CTL responses (Fig. 2-1). Introduction of surface polyethylene glycol layer generates 
monodisperse vesicles (PEG-NPs), enhancing their stability and promoting trafficking to the 
local lymph nodes, compared to the traditionally prepared freeze-thawed (FT) lysates or purified 
plasma membranes. These characteristics led to generation of strong OVA-specific T cell 
responses demonstrating greater anti-tumor protection in a prophylactic immunization. 
Additionally, therapeutic immunization with PEG-NPs aimed at combating established tumors 
led to markedly enhanced T cell responses and decreased tumor growth. Combinatory approach 
utilizing αPD-1 antibody therapy with PEG-NPs vaccination led to complete tumor regression in 
63% of animals and established protective immunity against future tumor re-challenge. These 
data demonstrate that PEGylated tumor cell membranes can serve as a potent cancer vaccine 
platform with strong anti-tumor efficacy. 
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Figure 2-1. Schematic representation of PEG-NPs preparation and therapy.  
B16F10 OVA cells are harvested from cell culture plates and used for s.c. inoculation of the 
tumor in the flank for C57BL/6 mice. Cells are also lysed through freeze-thaw cycling and 
sonicated to form nano-sized vesicles, aggregated with calcium, and the cytosolic fraction is 
washed away. PEGylation, removal of calcium with EDTA, and further wash steps are then 
performed. Finally, cholesterol-linked CpG is incorporated and the vaccine is administered 
subcutaneously at the tail base. PEG-NPs drain efficiently to the lymph nodes where they are 
taken up by DCs in order to activate antigen-specific cells, which enter the systemic circulation 
and home to the tumor. Once there, CTLs can recognize the antigen on tumor surface and kill 
cancer cells leading to tumor regression. 
 
2.3 Materials and Methods 
Cell culture 
B16F10 OVA cells, expressing exogenous model antigen ovalbumin with a 
transmembrane domain, were grown in RPMI 1640 media supplemented with 10% FBS, 100 
U/mL penicillin, and 100 μg/ml streptomycin. B16F10 OVA cells were kindly provided by the 
lab of Dr. Darrel Irvine (Massachusetts Institute of Technology; Cambridge, MA). Bone 
marrow-derived dendritic cells (BMDCs) were cultured as previously described [26]. Briefly, 
tibiae and femurs of C57BL/6 mice (Envigo) were harvested and the bone marrow extracted by 
flushing media through the bones using syringe equipped with a 26 gauge needle. Cells were 
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passed through a 40 µm strainer to remove debris, washed, and plated. Complete media (RPMI 
supplemented on 10% FBS, 100 U/mL penicillin, 100 μg/ml streptomycin, 50 μM β-
mercaptoethanol, and 20 ng/ml GM-CSF) was supplemented on day 3 and refreshed on days 6, 
8, and 10. BMDCs were used on days 8-12 from the suspended and loosely-adhered cell 
population.  
 
Lysate preparation 
Tissue culture-grown B16F10 OVA cells were trypsinized and washed three times with 
PBS. Cells were resuspended at 1 x 10
8
 cells/ml and lysed by freeze-thaw cycling (10 minutes in 
liquid nitrogen and 10 minutes in 37°C water bath; 6 cycles total). Low-speed centrifugation 
(100 x g, 10 minutes) was used to remove large debris and generate the Freeze-Thaw (FT) 
lysates from supernatant.  Sonicated lysates were obtained by probe-tip sonicating FT lysates for 
2 minutes on ice using 50% intensity setting (QSonica, 125 W/20 kHz sonicator) and collecting 
the supernatant after centrifugation (10,000 x g, 10 minutes). Cytosol and membrane fractions 
were generated by ultracentrifugation (200,000 x g; 1 hour) of sonicated lysates and collecting 
the supernatant and pellet, respectively. 
 
Nanoparticle preparation 
To generate PEGylated nanoparticles (PEG-NPs), we first aggregated the membrane 
fraction of cell lysates by adding 20 mM CaCl2 to sonicated cell lysates (6 mg/ml) in PBS, 
followed by incubation at 37°C for 1 hour. Particles were washed two times with PBS via 
centrifugation (20,000 x g; 5 minutes) and resuspended in PBS containing 100 mM EDTA and 
10 mg/ml Methoxy-Poly (Ethylene Glycol) - 1, 2-Distearoyl-sn-Glycero-3-
37 
 
Phosphoethanolamine-N (DSPE-PEG, 5 kDa average molecular weight; Laysan Bio, Inc.). 
Aggregates were fully dispersed by water-bath sonication (approx. 1 minute for 100 µl solution) 
and further incubated for 1 hour at 37°C to allow post-insertion of DSPE-PEG. The resulting 
PEG-NPs were purified by passing through Zeba desalting column (7K molecular weight cut-off, 
Thermo Fisher Scientific). 
 
Lysate and nanoparticle characterization 
Sample concentrations for all assays were standardized by total protein content as 
measured by MicroBCA Assay Kit (Thermo Scientific). SDS-PAGE was performed, followed 
by gel staining with Coomassie or transfer to a PVDF membrane for Western Blotting using 
antibodies against gp100 (Abcam), TRP2 (Santa Cruz), or ovalbumin (Abcam). Transmission 
electron microscopy images were obtained using JEOL 1400-plus microscope (JOEL USA) 
following sodium phosphotungstate negative staining. Particle size and zeta potential were 
measured and analyzed using dynamic light scattering (DLS, Malvern Zetasizer Nano Range) in 
PBS or ultrapure water, respectively. For stability studies, samples were incubated with PBS or 
10% FBS in PBS at 4°C (long term) or at 37°C while shaking (short term) as indicated in the 
figures. 
 
Protein uptake by dendritic cells  
In order to obtain fluorescently labeled lysate, trypsinized B16F10 OVA cells (2 million 
cells/ml) were incubated with 1 µM Oregon Green 488 carboxylic acid, succinimidyl ester 
(OG488, Thermo Fisher Scientific) in RPMI at 37°C for 10 minutes. Lysate was prepared as 
described above and then incubated with BMDCs for 24 hours. Cells were then washed, 
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trypsinized, and resuspended in FACS buffer (1% BSA in PBS) containing anti-CD16/32 
blocking antibodies. Cell were stained with CD11c antibody, washed, and analyzed via flow 
cytometry for OG488 signal. 
 
T cell expansion 
In vitro T cell expansion was examined by pulsing BMDCs (50,000 cells per well) 
overnight with lysate fractions or PEG-NPs at 1 mg/ml in 96-well plates. As indicated, 5 µg/ml 
CpG (IDT) or 1 µg/ml MPLA (Avanti Polar Lipids) were used as adjuvants. BMDCs were 
washed three time with PBS and CFSE-labeled T cells were added. First, OT-I transgenic CD8
+ 
T cells were purified from spleens using a negative selection kit (Stemcell Technologies). T cells 
were labeled with CFSE (1 µM concentration, 2 million cells/ml, 10 minutes in RPMI), washed, 
added to BMDC-containing wells, and allowed to expand for three days. Then, cells were 
collected by pipetting, blocked with FACS buffer containing anti-CD16/32 blocking antibodies, 
stained with anti-CD8α antibody, washed, and analyzed via flow cytometry for the dilution of 
the CFSE signal and count of surviving live T cells (DAPI
-/CD8α+). Proliferation Index was 
calculated using Proliferation Platform in FlowJo. 
 
Lymph node draining 
B16F10 OVA cell membranes were labeled with lipophilic DiD dye (1,1'-Dioctadecyl-
3,3,3',3'-Tetramethylindodicarbocyanine) by incubating 5 million cells/ml at 37°C for 10 minutes 
with 1 µg/ml DiD. Cells were washed three times with PBS to remove any unincorporated dye 
and processed into fractions and NPs as described above. Labeled formulations were normalized 
by DiD fluorescence and administered subcutaneously at the tail base of C57BL/6 mice (n = 4). 
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Two days post-injection, animals were euthanized, inguinal lymph nodes harvested, and imaged 
using In Vivo Imaging System (IVIS) to assess radiance efficiency. Then, lymph nodes were 
processed into single cell suspensions using a 40 µm cell strainer, washed, and blocked with 
FACS buffer containing anti-CD16/32 blocking antibodies. Next, we stained the cells for 
markers of macrophages (anti-F4/80 antibody) and DCs (anti-CD11c antibody), washed the 
cells, and analyzed with flow cytometry. 
 
Animal experiments 
All immunizations and tumor studies were performed according to the federal, state, and 
local guidelines. All work performed on animals was in accordance with and approved by 
University Committee on Use and Care of Animals (UCUCA) at University of Michigan, Ann 
Arbor. For all immunizations, cholesterol-modified CpG (IDT) was incubated with vaccine 
formulations at 37°C for 30 minutes prior to administration. For the prophylactic vaccination 
studies, 6-8 weeks old, female C57BL/6 mice were immunized subcutaneously at the tail base 
with 1 mg of total protein and 15 µg of CpG on days 0 and 14, followed by a challenge with 1 x 
10
6
 B16F10 OVA cells at s.c. flank on day 35. For the therapeutic vaccination studies, 6-8 weeks 
old, female C57BL/6 mice were inoculated with 2 x 10
5
 B16F10 OVA cells at s.c. flank on day 
0, and immunized with vaccine formulations (1 mg of total protein and 15 µg of CpG ) on days 5 
and 12 with or without co-administration of anti-PD-1 IgG (i.p.; 100 µg per mouse per injection) 
on days 6, 9, 13, and 16. Tumor size was measured every other day and the volume determined 
using the following formula: length x width x width x 0.50. 
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Tetramer staining 
Cytotoxic T lymphocyte responses were analyzed by tetramer staining one week after 
each immunization as described before [27]. Briefly, 150 µl of blood was collected and red blood 
cells were removed with ACK lysis buffer. Washed PBMCs were blocked with FACS buffer 
containing anti-CD16/32 blocking antibodies and stained with H-2Kb OVA Tetramer-
SIINFEKL-PE (MBL International), followed by staining with anti-CD8 antibody. Cells were 
washed, dead cells were labeled with DAPI, and the final suspension analyzed by flow 
cytometry. 
 
Statistical analyses 
For animal studies, mice were randomized to match similar average volume of the 
primary tumors, and all procedures were performed in a non-blinded fashion. Statistical analysis 
was performed with Prism 6.0 software (GraphPad Software) by an unpaired student’s t-test and 
one-way or two-way ANOVA with Tukey’s comparisons post-test, as indicated. Statistical 
significance for survival curve was calculated by the log-rank test. Statistical significance is 
indicated as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. 
 
2.4 Results and Discussion 
Characterization of tumor cell lysate  
In this study, we aimed to use tumor cell lysate to generate adaptive anti-tumor immune 
responses, and we have utilized B16F10 OVA murine melanoma cells expressing the model 
antigen ovalbumin (OVA) on their plasma membrane. We generated sonicated cell lysate by 
freeze-thaw cycles, followed by probe-tip sonication and centrifugation to remove large debris. 
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Examination of cell lysate under transmission electron microscopy (TEM) demonstrated the 
presence of nano-sized vesicles (Fig. 2-2A), which we suspected to be self-assembled remnants 
of the plasma membrane. Membrane fraction was separated via ultracentrifugation and 
demonstrated to contain various proteins as shown by gel electrophoresis, followed by 
Coomassie staining (Fig. 2-2B). We performed Western blotting to test for the retention of 
various tumor-associated antigens in the membrane fraction. Proteins with transmembrane 
domain, such as endogenous glycoprotein 100 (gp100) and tyrosine-related protein 2 (TRP2) 
[28, 29], along with the model antigen OVA (with a transmembrane domain in our B16F10 OVA 
cell line) were detected in varying levels in either the whole cell lysate or the membrane fraction 
(lane 1 and 2, respectively. Fig. 2-2B). 
 
 
Figure 2-2. Characterization of membrane fraction of cell lysates.  
A. TEM image of cell lysates show nano-sized membrane structures. B. Wide protein repertoire 
from whole cell lysate (lane 1) is retained within the membrane fraction (lane 2) as seen via 
coomassie staining (top panel). Tumor-associated antigens (gp100 and TRP2) and model antigen 
(OVA) incorporation was determined by Western Blot analysis (bottom three panels). C. 
Fluorescently-labeled lysates, cytosol fraction, and membrane fraction were pulsed to dendritic 
cells and the relative protein uptake analyzed by flow cytometry. D. Dendritic cells were pulsed 
with lysate fractions with or without MPLA and co-cultured with OT-I OVA-specific T cells. T 
cell proliferation was measured by the dilution of CFSE dye via flow cytometry. Mean ± SD are 
shown. Statistical analysis was performed using one-way ANOVA comparison with Tukey’s 
multiple comparison test (*** = p < 0.001, **** = p < 0.0001). 
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When incubated with bone-marrow derived dendritic cells (BMDCs) in vitro, membrane-
associated proteins were preferentially taken up by DCs (P < 0.0001, Fig. 2-2C), in contrast to 
inefficient uptake of cytosolic proteins by DCs, suggesting that proteins associated with 
membrane vesicles have increased interactions with antigen-presenting cells (APCs), leading to 
enhanced phagocytosis of cellular proteins. We hypothesized that this enhanced uptake and 
eventual presentation of antigens in the context of major histocompatibility complex-I (MHC-I) 
would result in activation of antigen-specific cytotoxic T lymphocytes (CTLs). To test this, we 
isolated OVA-specific CD8α+ T cells from OT-I transgenic mice, co-cultured them with lysate-
pulsed BMDCs, and examined proliferation of OT-I CD8α+ T cells. Cell membrane fraction, 
characterized by enhanced DC uptake and high antigen content, led to significantly increased T 
cell expansion in vitro (P < 0.001, Fig. 2-2D), compared with the cytosolic or whole lysate 
fractions. Furthermore, as immunostimulatory agents induce strong T-cell activation and 
proliferation, we added monophosphoryl lipid A (MPLA), a Toll-like receptor (TLR) 4 agonist. 
Similar trend of T cell expansion was observed after addition of MPLA, with the membrane 
fraction containing MPLA generating the greatest extent of CD8α+ T cell proliferation among all 
the groups (P < 0.001, Fig. 2-2D). These results showed that the membrane fraction of cell lysate 
contained vesicular nanostructures with tumor-associated antigens and that DCs pulsed with 
these membrane vesicles cross-primed antigen-specific CD8α+ T cell responses in vitro. 
 
Preparation and characterization of PEG-NPs 
Having shown induction of CD8α+ T cells with membrane vesicles in vitro, we sought to 
further characterize them along the preparation procedure and improve their overall stability for 
the subsequent vaccination studies in vivo (see below).  When B16F10 OVA cells were 
43 
 
harvested and cycled between liquid nitrogen and 37°C water bath, followed by low speed 
centrifugation, the resulting supernatant contained large, poly-disperse structures, which we 
termed freeze-thawed (FT) lysate. Analyses with dynamic light scattering indicated that FT 
lysate contained vesicles with 610 ± 60 nm hydrodynamic diameter, the polydispersity index 
(PDI) of 0.67 ± 0.12, and zeta potential of -30 mV ± 1 mV (Fig. 2-3A).  Further probe-tip 
sonication and removal of large debris via high speed centrifugation yielded smaller and  
 
 
Figure 2-3. Characterization PEG-NPs.  
A. Particle size, PDI, and zeta potential  were determined by dynamic light scattering analysis. B. 
Particles were incubated over a period of four weeks in PBS or 10%/90% FBS/PBS at 4°C. 
Stability was assessed by determining particle sizes and PDIs within that duration. C. Particles 
were incubated over a period of three days in PBS or 10%/90% FBS/PBS at 37°C. Aggregation 
was assessed by determining particle sizes and PDIs within the timeframe and mean ± SD are 
shown. 
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monodisperse membrane vesicles with 180 ± 2 nm hydrodynamic diameter, PDI of 0.28 ± 0.02, 
and zeta potential of -25 mV ± 1 mV (Fig. 2-3A).   
 We examined the stability of FT lysate stored at 4°C in PBS or 10% FBS-containing 
PBS over time. Our data indicated that FT lysate increased in size from 610 nm to approximately 
1 micron in both conditions with the PDI values increasing beyond 0.70 (Fig. 2-3B). 
Endogenous nano-vesicles present in the sonicated lysate preparation (without PEGylation) also 
aggregated over the four-week period in PBS increasing in size from 180 nm to 280 nm and 
becoming more polydisperse (PDI > 0.5) (Fig. 2-3B). Instability of endogenous nano-vesicles 
was exacerbated in the presence of 10% FBS, causing sonicated lysate to aggregate within just 
one week (Fig. 2-3B).  
To address potential aggregation of native cellular membrane vesicles and to promote 
draining of these vesicles to local lymph nodes (LNs) upon s.c. administration in vivo, we have 
introduced a polyethylene glycol (PEG) layer on these cell membrane vesicles (Fig 2-1). First, 
sonicated lysate containing membrane vesicles was incubated at 37°C with calcium to promote 
membrane fusion and aggregation, which allowed for facile collection of membrane vesicles via 
simple table-top centrifugation. Washed particles were then mildly sonicated together in the 
presence of lipid-conjugated PEG (DSPE-PEG) and EDTA to chelate any remaining calcium. 
Upon desalting column purification, the resulting PEGylated cell membrane particles (PEG-NPs) 
exhibited 130 ± 3 nm hydrodynamic diameter, PDI of 0.20 ± 0.02, and zeta potential of -39 mV 
± 2 mV (Fig. 2-3A). 
In sharp contrast to the gradual aggregation of endogenous membrane vesicles during 
long-term storage as shown above (Fig. 2-3B), the size of PEG-NPs stored at 4°C in PBS or 10% 
FBS-containing PBS was maintained stably at ~130 nm with the PDI remaining below 0.25 for 
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the course of four week study. Importantly, when we increased the storage temperature to 37°C 
to better simulate in vivo conditions, we observed even bigger differences. Endogenous sonicated 
nano-vesicles (without PEGylation) rapidly aggregated within 1 day at 37°C in either PBS or 
10% FBS-PBS, whereas PEG-NPs maintained their size and monodispersity for at least 3 days 
(Fig. 2-3C). Overall, PEG-NPs outperformed the other lysate preparations during the simulated 
stability testing as shown by complete lack of aggregation. These results suggested that PEG-
NPs may drain efficiently to local LNs following administration, whereas other lysate 
formulations may aggregate in vivo, potentially limiting their draining to LNs upon s.c. 
administration.  
 
In vitro T cell activation  
We next tested the impact of various cell lysate formulations on cross-presentation of 
antigens by DCs and cross-priming of antigen-specific T cells in vitro. We pulsed BMDCs with 
lysate formulations for 1 day and performed T cell expansion assay with OT-I CD8α+ T cells, 
using media and OT-I peptide (sequence = SIINFEKL) as negative and positive controls, 
respectively. Overall, stimulation of DCs with CpG, a potent TLR9 agonist composed of a single 
stranded DNA containing unmethylated CG motifs, was more effective at expansion of OT-I 
CD8α+ T cells, compared with the use of MPLA (Fig. 2-4). Based on these results, we chose to 
use CpG as the adjuvant for the remainder of our experiments.  
BMDCs pulsed with PEG-NPs effectively induced T cell activation and proliferation, as 
evidenced by extensive dilution of the CFSE dye within the surviving T cells (Fig. 2-5A,B). 
CFSE dilution induced by the PEG-NPs in vitro was on par with the membrane fraction but more 
effective than that induced by FT lysate (P < 0.0001, Fig. 2-5A,B). The proliferation index,  
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Figure 2-4. CFSE dilution assay.  
Dendritic cells were pulsed with controls  and lysate formulations overnight and then co-cultured 
with CFSE-labeled OT-I T cells for three days. Average percentage of proliferated T cells after 
three days of culture are represented by percentage of cells with diluted CFSE fluorescence. 
Relative count of live T cells was examined within the CD8α+ population. Mean ± SD are 
shown.  
 
which reports the average number of divisions that proliferating cells undergo [30], was 
significantly higher for the PEG-NP group, compared with FT lysate, cytosolic or membrane 
fractions (P < 0.001, Fig. 2-5C). Additionally, we have examined the overall number of T cells 
at the end of experiments, as these data provide context to the CFSE dilution results. The number 
of live T cells remaining at the end of 3 day co-culture period was at least two-fold greater for 
the PEG-NP group, compared with the FT lysate or the membrane fraction group (P < 0.001, 
Fig. 2-5D). Notably, the PEG-NPs treatment sustained comparable number of live T cells as the 
SIINFEKL positive control group (Fig. 2-5D), indicating strong induction and maintenance of T-
cell proliferation supported by the PEG-NPs. Taken together, these results suggest that the PEG-
NPs are taken up and processed effectively by DCs, leading to potent cross-priming of antigen-
specific CD8α+ T cells.  
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Figure 2-5. T cell expansion in vitro.  
Dendritic cells were pulsed with controls  and lysate formulations overnight and then co-cultured 
with CFSE-labeled OT-I T cells for three days. A. Representative FACS histograms 
demonstrating CFSE dilution within proliferating OT-I T cells are shown. B. Average percentage 
of proliferated T cells after three days of culture are represented by percentage of cells with 
diluted CFSE fluorescence. C. Proliferation index was determined by FlowJo analysis software. 
D. Relative count of live T cells was examined within the CD8α+ population. Mean ± SD are 
shown. Statistical analysis was performed using one-way ANOVA comparison with Tukey’s 
multiple comparison test (** = p< 0.01, *** = p < 0.001, **** = p < 0.0001). 
 
 
Lymph node draining 
PEGylation generally provides an advantage for subcutaneous (s.c.) administration of 
nano-formulations, by drastically reducing interactions between the formulation and cells or 
serum proteins, thus promoting their trafficking to draining lymph nodes (dLNs) [31]. To 
determine the level of particle localization in dLNs at the whole tissue and cellular levels, lysate 
formulations were labeled with DiD, a lipophilic dye, and administered s.c. at the tail base. After 
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two days, inguinal dLNs were extracted, and the relative draining efficiency was assessed via 
whole LN imagining and flow cytometry. PEG-NPs exhibited significantly increased trafficking 
to dLNs, compared with the membrane fraction (P < 0.01, Fig. 2-6A). We have also examined 
subset of APCs that are responsible for lysate uptake. PEG-NPs were efficiently taken up by 
F4/80+ macrophages as well as DCs (Fig. 2-6B). These results demonstrated the ability of PEG-
NPs to drain efficiently to dLNs and localize within APCs for potential antigen processing and 
presentation.  
 
In vivo T cell activation and protective immunization 
Next, we performed immunization studies in vivo to examine T cell responses induced by 
FT lysate and PEG-NPs. We immunized C57BL/6 mice on days 0 and 14 with FT lysate or PEG-
NPs containing 1 mg of total protein and 15 µg of CpG per mouse (Fig. 2-6C). On day 7, 1 week 
post-prime, we examined peripheral blood mononuclear cells (PBMCs) for OVA-specific 
CD8α+ T cell responses via tetramer staining. We observed that immunization with PEG-NPs 
increased the frequency of OVA-specific CD8α+ T cells by 5-fold, compared with FT lysate 
group although this difference was not statistically significant (P = 0.25, Fig. 2-6D). We then 
examined the efficacy of vaccine formulations to induce protective immune responses against 
tumor challenge. Pre-immunized mice were inoculated at s.c. flank with 10
6
 B16F10 OVA cells 
(10-fold more cells than necessary to establish tumors in naïve animals) (Fig. 2-6C). Mice 
vaccinated with FT lysate exhibited the median survival time of 42 days, compared with 17 days 
in the PBS control group (Fig. 2-6E). Importantly, vaccination with PEG-NPs significantly 
extended the median survival time to 55 days (P < 0.01 versus PBS or FT lysate, Fig. 2-6E), and 
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50% of the animals remained completely free of tumor for at least 80 days, demonstrating the 
potency of PEG-NPs to elicit protective immune responses against tumor cells. 
 
 
 
 
 
Figure 2-6. In vivo lymph node draining and prophylactic immunization.  
Cell lysate formulations were labeled with DiD fluorescent lipophilic dye and administered 
subcutaneously at the tail base. A. Whole lymph node imaging is shown along with analysis of 
the radiance efficiency measured by IVIS two days after injection. B. Harvested lymph nodes 
were dissociated into single cell suspension and analyzed for DiD uptake by macrophages and 
dendritic cells via flow cytometry. C. Mice were immunized twice on day 0 and 14 followed by 
administration of  ten-fold more cells than necessary to ensure tumor engraftment in immunized 
animals. D. OVA-specific CD8
+
 T cell population among PBMCs was determined via tetramer 
staining. E. Overall survival following s.c. tumor challenge on day 35 is shown. Mean ± SEM 
values are shown. Statistical analysis was performed using (A) one-way ANOVA comparison 
with Tukey’s multiple comparison test; and (E) Log-rank (Mentel-Cox) test (* = p < 0.05, ** = p 
< 0.01). 
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Figure 2-7. Safety of PEG-NPs.  
A Mice were inoculated with B16F10 OVA on day 0 and immunized twice on days 5 and 12. B. 
Weight of the animals was recorder starting on the day of first immunization and mean ± SEM 
fold change is shown for each group.  
 
Therapeutic immunization 
B16F10 OVA tumors were established via s.c. injection of 2 x 10
5
 tumor cells on the 
right flank, and when the tumors were palpable on day 5, we vaccinated animals with either FT 
lysate or PEG-NPs on days 5 and 12 (Fig. 2-8A). Throughout the study, we observed no changes 
in animal health following administration of our vaccines, as demonstrated by normal behavior 
and maintained body weight (Fig. 2-7). Vaccination with FT lysate slowed the tumor growth, 
compared with the PBS control (P < 0.0001 for days 19 and 21, Fig. 2-8B,C). Importantly, PEG-
NPs treatment exerted significantly enhanced anti-tumor efficacy, further decreasing tumor 
growth compared with the FT lysate group (P < 0.001 for day 21) (Fig. 2-8B,C). Importantly, 
the PEG-NPs treatment elicited robust antigen-specific CD8α+ T cell responses on day 12, 
characterized by 7.4-fold and 3.7-fold increases in the frequency of OVA-specific CD8α+ T cells 
among peripheral blood mononuclear cells (PBMCs), compared with PBS (P < 0.001) and FT  
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Figure 2-8. Therapeutic treatment against B16F10 OVA.  
A. Mice were inoculated with B16F10 OVA tumor s.c. in the flank on day 0 and immunized on 
days 5 and 12. B-C. Tumor growth curves for individual mice within groups and summary are 
shown. D. Tetramer staining analysis via flow cytometry was performed to determine OVA-
specific CTL responses among PBMCs (day 12; one week post-prime immunization). E. Overall 
survival is shown. Mean ± SEM are shown for panels C and D. Statistical analysis was 
performed using (C) two-way ANOVA with Tukey’s multiple comparisons test compared to 
PBS + αPD-1 (black asterisks) and FT Lysate + αPD-1 (blue asterisks); (D) one-way ANOVA 
comparison with Tukey’s multiple comparison test; and (E) Log-rank (Mentel-Cox) test (* = p < 
0.05, ** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001). 
 
lysate (P < 0.01) groups, respectively (Fig. 2-8D). These strong T-cell responses induced by 
PEG-NPs translated to increased animal survival, as mice treated with PEG-NPs exhibited the 
median survival of 55 days, compared with 22 and 27 days for PBS (P < 0.001) and FT lysate 
groups (P = 0.12), respectively (Fig. 2-8E). Notably, antigen-specific CD8α+ T cell responses 
induced by PEG-NPs in these tumor-bearing animals (Fig. 2-8D) was greater, compared with 
those observed in non-tumor bearing animals post PEG-NPs treatments (Fig. 2-6C), suggesting 
that the presence of antigen-expressing tumors boosted the effects of vaccination. 
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Combination therapy approach with immune checkpoint blockade 
Immunosuppressive tumor microenvironment is currently a major challenge in allowing 
patients’ endogenous immune responses from controlling cancer. Blocking the interaction 
between PD-1 and PD-L1, primarily expressed on T lymphocytes and tumor cells, respectively, 
allows T cells to engage and kill cancer cells, as demonstrated by recent success of immune 
checkpoint inhibitors in the clinic [32]. Here, we aimed to further amplify T cell responses 
induced by PEG-NPs with co-administration of an immune checkpoint inhibitor. Briefly, 
C57BL/6 mice were inoculated at s.c. right flank with 2 x 10
5
 B16F10 OVA tumor cells, and we 
administered PEG-NPs or FT lysate on days 5 and 12 together with intraperitoneal 
administration of αPD-1 IgG (100 µg per mouse per dose) on days 1 and 4 after each  
immunization (Fig. 2-9A). Tumor-bearing mice treated with FT lysate + αPD-1 IgG 
therapy exhibited similar rate of tumor growth and median survival as animals treated with the 
αPD-1 IgG monotherapy (Fig. 2-9B,C), indicating the aggressive and poorly immunogenic 
nature of B16F10 OVA tumors. In sharp contrast, the combination of PEG-NPs + αPD-1 IgG 
therapy markedly decreased tumor growth, compared to αPD-1 monotherapy as well as the FT 
lysate + αPD-1 treatment (P < 0.0001, day 23, Fig. 2-9B,C). Analysis of T cell responses in 
peripheral blood indicated that the PEG-NPs + αPD-1 IgG combination therapy induced 4.2-fold 
higher frequency of OVA-specific CD8α+ T cell responses, compared with the FT lysate + αPD-
1 treatment group (P < 0.0001, Fig 2-9D). Overall, the PEG-NPs + αPD-1 IgG combination 
therapy resulted in complete eradication of the tumors in 63% of animals without reaching the 
median survival for the whole duration of the study. In contrast, animals treated with FT lysate + 
αPD-1 IgG exhibited only 13% response rate with the median survival of 28 days (P < 0.01, Fig 
2-9E). 
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Figure 2-9. Therapeutic treatment against B16F10 OVA.  
A. Mice were inoculated with B16F10 OVA tumor s.c. in the flank on day 0 and immunized on 
days 5 and 12 with anti-PD-1 co-administration. B-C. Tumor growth curves for individual mice 
within groups and summary are shown. D. Tetramer staining analysis via flow cytometry was 
performed to determine OVA-specific CTL responses among PBMCs (day 12; one week post-
prime immunization). E. Overall survival is shown. F. Mice were rechallenged with B16F10 
OVA on day 60 together with a group of naïve mice and the overall survival is shown. Mean ± 
SEM are shown for panels C and D. Statistical analysis was performed using (C) two-way 
ANOVA with Tukey’s multiple comparisons test compared to PBS + αPD-1 (black asterisks) 
and FT Lysate + αPD-1 (blue asterisks); (D) one-way ANOVA comparison with Tukey’s 
multiple comparison test; and (E) Log-rank (Mentel-Cox) test (** = p < 0.01, *** = p < 0.001 
and **** = p < 0.0001). 
 
We next determined if immune responses induced by the original treatment regimen 
established long-term systemic immunity against tumor recurrence. The survivors from the 
previous study (on day 60 of the original study) along with naïve control animals were 
inoculated with 2 x 10
5
 B16F10 OVA tumor cells at the contralateral s.c. flank. None of the re-
challenged survivors developed tumors for 50 days, whereas all naïve animals succumbed to 
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tumor growth with the median survival of 23 days (P < 0.01, Fig 2-9F). These results 
demonstrated that the PEG-NPs + αPD-1 IgG combination therapy elicited long-term protective 
immunity against the tumor cells.  
 
Therapeutic immunization against large tumors 
To determine if our vaccine approach can combat large tumors, we began therapy on day 
10 after inoculation, once tumors have reached on average 70 mm
3
 in volume (Fig. 2-10A). CTL 
responses after PEG-NPs administration were comparable to the day 5 immunization (3.66% vs 
2.90% OVA-specific T cell frequency) and stronger than PBS- and FT-lysate-treated controls (P 
< 0.0001, Fig. 2-10D). There was a significant decrease in the rate of tumor growth resulting in a 
smaller tumor burden for PEG-NPs compared to the FT-Lysate control (P < 0.05, Fig. 2-10B,C). 
However, due to the persistence of the tumors, there was only a modest increase in the median 
survival to 35 days, compared to PBS (21 days, P < 0.01) and FT lysate (27 days, P < 0.01) 
groups (Fig. 2-8E). 
We hoped that αPD-1 administration will assist with combating the large tumor burden of 
mice treated starting on da 10. However, even with strong CTL responses (5.17% OVA-specific 
T cell frequency), there was limited improvement over αPD-1 monotherapy in terms of tumor 
growth and overall survival (Fig. 2-10F-J). We suspect that the large and established tumors 
may prevent effective T cell infiltration and thus decrease their ability to control further 
progression. Additionally, the rapid proliferation of great number of tumor cells may outcompete 
the killing potential of the immune system, indicating the need for tumor debulking approaches, 
such as surgery or photothermal therapy.  
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Figure 2-10. Therapeutic treatment against large B16F10 OVA tumors.  
A. Mice were inoculated with B16F10 OVA tumor s.c. in the flank on day 0 and immunized on 
days 10 and 17. B-C. Tumor growth curves for individual mice within groups and summary are 
shown. D. Tetramer staining analysis via flow cytometry was performed to determine OVA-
specific CTL responses among PBMCs (day 17; one week post-prime immunization). E. Overall 
survival is shown. F. Mice were inoculated with B16F10 OVA tumor s.c. in the flank on day 0 
and immunized on days 10 and 17. Anti-PD-1 therapy was administered and 4 days after each 
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immunization. G-H. Tumor growth curves for individual mice within groups and summary are 
shown. D. Tetramer staining analysis via flow cytometry was performed to determine OVA-
specific CTL responses among PBMCs (day 17; one week post-prime immunization). E. Overall 
survival is shown. Mean ± SEM are shown for panels C and D. Statistical analysis was 
performed using (D, I) one-way ANOVA comparison with Tukey’s multiple comparison test; 
and (E, J) Log-rank (Mentel-Cox) test (* = p < 0.05, ** = p < 0.01, and **** = p < 0.0001). 
 
 
In order to establish if humoral responses contribute to the anti-tumor activity, we 
examined the antibody and CD4+ T cell responses in tumor-bearing animals. Mice were 
inoculated with B16F10 OVA cells, immunized on days 10 and 17, treated with αPD-1 as 
indicated before, and serum and blood samples were collected on day 22 (Fig. 2-11A). 
Incubation of sera from the immunized animals with live tumor cells and staining with secondary 
anti-mouse IgG showed no differences in the presence of tumor-specific antibodies (Fig. 2-11B.) 
Additionally, PBMCs isolated from the blood sample, were cultured together with OT-II peptide, 
the MHC-II epitope of ovalbumin, to determine CD4+ T cell reactivity in an ELISpot 
experimental setting. While the immune responses were elevated in the animals treated with FT 
lysate, PEG-NPs, αPD-1, or combination of therapies, there were no differences when compared 
to media control, suggesting presence of nonspecific immune activation (Fig. 2-11C).  
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Figure 2-11. Humoral responses against large B16F10 OVA tumors.  
A. Mice were inoculated with B16F10 OVA tumor s.c. in the flank on day 0 and immunized on 
days 10 and 17. Anti-PD-1 therapy was administered and 4 days after each immunization where 
indicated. B. Sera were collected on day 22 and incubated with live tumor cells followed by anti-
mouse-IgG-PE secondary antibody staining. C. PBMCs were obtained from a blood sample and 
incubated with media control or OT-II peptide to determine CD4 T cell OVA-specific responses. 
Mean ± SEM are shown. Statistical analysis using one-way and two-way ANOVA comparison 
with Tukey’s multiple comparison test showed no statistical differences between the groups. 
 
2.5 Conclusions 
In this study, we have demonstrated that the endogenous liposome-like plasma membrane 
structures present in cancer cell lysates can be engineered to exhibit stable characteristics and 
enhanced local lymph node draining via PEGylation. This cancer vaccine approach can elicit 
strong CTL responses against model antigen OVA, resulting in prophylactic and therapeutic 
efficacy against murine melanoma. In combination with immune checkpoint blockade, 
vaccination with engineered membrane nano-vesicles resulted in complete regression in tumors 
of 63% of the animals and established long-term immunity against tumor cell re-challenge. 
Overall, we have provided concrete evidence that use of cancer cell membranes for elicitation of 
anti-tumor immune responses is a feasible and promising approach for cancer immunotherapy.  
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Chapter 3: Dendritic Cell Membrane Vesicles for Activation and Maintenance of Antigen-
specific T Cells 
 
3.1 Abstract 
 Cancer immunotherapy has undergone a dramatic transformation over the past decade, 
due to successes of the immune checkpoint blockade and CAR T cell technology, fueling further 
efforts to enhance these treatments. Vaccination has traditionally been associated with preventing 
infections, but great progress had been made in the field of cancer vaccines, which can synergize 
with the existing immune therapies to boost the level of available cytotoxic T cells to fight 
tumors. In this study, we have developed a nano-sized dendritic cell membrane vesicles (DC-
MVs) capable of activating antigen presenting cells as well as delivering peptide antigens. DC-
MVs successfully led to maturation of dendritic cells and promoted T cell survival and 
proliferation in vitro. These effects were also observed in vivo, where mice adoptively 
transferred with antigen-specific T cells exhibited greater frequency of those T cells following 
vaccination with DC-MVs and peptide antigen compared to peptide antigen alone. Additionally, 
DC-MVs vaccination led to enhanced levels of endogenous T cell responses against model 
antigen ovalbumin in an OVA-expressing tumor model. These results suggest that DC-MVs are a 
potentially attractive platform for further development as a peptide-based vaccine for cancer 
immunotherapy. 
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3.2 Introduction 
 Cytotoxic T lymphocyte (CTL) responses have evolved to eliminate virally and 
bacterially infected cells and have been responsible for keeping tumors at bay as demonstrated 
by increased cancer rates amongst immunocompromised individuals [1]. In the recent years, 
cancer immunotherapy focused on the CTL activation and responses has shown great promise by 
generating efficacious responses and obtaining clinical approval. Immune checkpoint blockade 
has released the brakes from the immunosuppressive tumor environment allowing for 
demonstration of therapeutic effects following cancer vaccination [2]. At the same time advances 
in affordable next generation sequencing and technology necessary for peptide synthesis 
compliant with current good manufacturing practices (cGMP), allowed for discovery and 
characterization of neo-antigens in variety of tumor types [3, 4]. 
 Due to the exceptional mutational rate of dividing tumor cells, they are very likely to 
harbor single amino acid changes or reading frame shifts randomly generating brand new peptide 
sequences [5]. While these mutations may not necessary drive or even contribute to the cancer 
growth, they may provide a therapeutic target. The existence of a brand new peptide sequence 
may lead to alternative proteasomic degradation, association with and affinity for major 
histocompatibility complex class I (MHC-I), and most importantly recognition by CTLs. All of 
these characteristics have the ability to change the identity of the peptide from self-antigen to 
immunogenic neo-antigen, leading to immune responses and antigen-dependent eradication of 
the tumor cells. These discoveries and tremendous amount of work over the past decade had led 
to development of effective cancer vaccines evaluated in small scale clinical trials [6, 7]. 
 In this study we had focused on the development of allogenic cell-derived vehicle for 
antigen peptide delivery in order to promote immune responses, with the goal of generating neo-
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antigen-specific T cell immunity in the long run. We had utilized cell membrane preparation 
technology developed by our lab in order to generate dendritic cell membrane vesicles (DC-
MVs) from matured antigen-presenting cell population. We had sought to utilize these to 
function by delivering peptides to the lymph nodes, as has been seen by our previous utilization 
of PEGylated cancer cell membranes (unpublished data). Successful uptake and activation of 
antigen presenting cells (APCs) would allow for antigen presentation and T cell proliferation. 
 Here, we show that MPLA-activate DC-MVs were able to effectively load model 
antigenic SIINFEKL peptide onto the particle surface and promote activation of immature DCs 
and stimulate T cells for enhanced maintenance and proliferation in vitro (Fig 3-1). In addition, 
following adoptive cell transfer, OT-I T cell population was activated prompting strong 
proliferation in vivo after immunization with DC-MVs. Finally, tumor-bearing animals 
exhibiting low levels of endogenous OVA-specific responses were immunized with our 
formulation and showed enhanced frequency of antigen-specific T cells. Taken together, these 
results demonstrate that the DC-MV formulation can load peptides onto the particle surface and 
deliver it to the site of action along with its endogenous immunostimulatory function. This 
outcome provides promise for this peptide-based vaccination approach for further development 
in the field of neo-antigen-specific cancer immunotherapy. 
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Figure 3-1. Schematic representation of DC-MVs.  
Immature DCs are stimulated with MPLA, prepared in PEG-NPs, and loaded with antigen 
peptide to generate DC-MVs. In vivo administration results in lymphatic drainage, uptake by 
DCs promoting maturation and antigen display, and antigen-specific T cell activation and 
proliferation. 
 
 
3.3 Materials and Methods 
Cell Culture 
 Bone marrow-derived dendritic cells (BMDCs) were generated as previously described 
[8]. Briefly, 6- to 12-week old C57BL/6 or BALB/c mice were euthanized and the tibiae and 
femurs harvested. The bones were cut on each side and flushed in order to extract the bone 
marrow, which was then dissociated into single cell suspension and passed through a 40 µm 
strainer. Cells were spun down, resuspended at 2 x 10
5
 cells per ml of complete media (RPMI 
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/ml streptomycin, 50 μM β-
mercaptoethanol, and 20 ng/ml GM-CSF), and plated in non-treated petri dishes for continuous 
culture. Media was added on day 3 and replenished on days 6 and 8. Loosely adherent cells 
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(immature DCs) were collected via gentle pipetting and washed with PBS prior to further use. 
B16F10 OVA cells were kindly provided by Dr. Darrell Irvine (Massachusetts Institute of 
Technology; Cambridge, MA) and cultured in RPMI supplemented with 10% FBS, 100 U/mL 
penicillin, 100 μg/ml streptomycin. 
 
Western Blot Analysis 
 BMDCs were plated in culture-treated dishes and allowed to adhere overnight followed 
by stimulation with 1 µg/ml of MPLA for 24 hours. Suspended cells were harvested (MPLA-S 
population), plates were washed, and Accutase was added to facilitate further cell dissociation 
from the plates for 30 minutes. The remainder of the cells was removed with a cell scraper 
(MPLA population). Untreated cells had both of the suspended and strongly adhered populations 
combined for analysis (NO TX). Harvested cells were lysed through freeze-thaw cycling 
between liquid nitrogen and 37°C followed by probe-tip sonication to generate whole cell 
lysates. Fractionation was achieved through consecutive centrifugation of supernatants from 
previous steps to generate cell debris (pellet after 1000 x g, 10 minutes), mitochondria (pellet 
from 20,000 x g, 10 minutes), and cytosol and membrane fractions (supernatant and pellet, 
respectively, from 100,000 x g, 1 hour). Protein content was analyzed by microBCA assay 
(Thermo), 20 µg of total protein was loaded onto 4-12% gradient gel to perform SDS-PAGE, and 
transferred to PVDF membrane using the iBlot system (Thermo). Membranes were blocked with 
5% milk solution and probed with anti-CD80 (R&D Systems), anti-CD86 (R&D Systems), and 
cytochrome c (Santa Cruz) primary antibodies overnight at 4°C. After three washes, membranes 
were incubated with secondary HRP-linked antibodies for 1 hour at room temperature. 
66 
 
Following further washes, ECL reagent was used to develop the Western Blots for imagining 
with FluorChem M (ProteinSimple). 
 
DC-MV Preparation and Peptide Loading 
 Dendritic cell membrane vesicles (DC-MVs) were generated from sonicated cell lysates 
following removal of large debris and organelles via centrifugation (10,000 x g, 10 minutes). 
Lysates were adjusted to 6 mg/ml concentration and incubated with 20 mM CaCl2 for 1 hour to 
promote fusion and aggregation of membranes allowing for washes using table-top 
centrifugation (20,000 x g, 5 minutes). DC-MVs were then resuspended with mild water bath 
sonication in 10 mg/ml DSPE-PEG 100 mM EDTA solution prompting calcium chelation and 
surface coating with polyethylene glycol. Finally, vesicles were passed through PBS-equilibrated 
Zeba desalting column to remove excess EDTA, calcium, and DSPE-PEG to generate DC-MVs. 
 SIINFEKL or fluorescently labeled SIINFEK(FITC)L peptides (Genscript) were loaded 
at 100 µg/ml onto the DC-MV surface via incubation at 37°C at varying DC membrane 
concentrations (10.0, 2.5, and 1.0 mg/ml in PBS). Loading efficiency was determined after 
samples were passed two times through 40 kDa Zeba desalting column via plate-based 
fluorescence assay.  
 
BMDC Maturation 
 Day 10 differentiated dendritic cells were added to 96-well plates at 1 x 10
5
 cells per well 
and allowed to adhere overnight. MPLA (1 µg/ml), unstimulated DC-MVs, and (MPLA)DC-
MVs were incubated with  DCs for 24 hours and then washed away with PBS. Cells were 
trypsinized and lifted off of the plate, washed twice with FACS buffer (1% bovine serum 
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albumin in PBS), and resuspended with anti-CD16/32 antibody to promote blocking of the Fc 
receptor. Then, cells were stained with anti-CD40 and anti-CD80 fluorescently-labeled 
antibodies, incubated for 30 minutes on ice, and washed twice more with FACS buffer. Finally, 
samples were resuspended in FACS buffer containing 1 µg/ml DAPI and analyzed with ZE5 Cell 
Analyzer (Bio Rad). Gating and analysis was performed using FlowJo software. 
 
T Cell Proliferation In vitro 
 In vitro T cell proliferation was performed using OVA-specific primary T cells. Briefly, 
6- to 12-week old OT-I transgenic mouse was euthanized and its spleen harvested and processed 
into single cell suspension. Red blood cells were removed by three-minute incubation with ACK 
lysis buffer (Gibco) and CD8α+ T cells were separated using negative selection kit (StemCell 
Technologies). Cells were then adjusted to a concentration of 4 million cells / ml in RPMI and 
combined with equivalent volume of 2 µM CFSE solution to be incubated at 37°C for ten 
minutes allowing fluorescent labeling. Reaction was quenched with FBS-containing media and 
the cells were washed prior to counting and resuspending in complete T cell media (RPMI 
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/ml streptomycin, 50 μM β-
mercaptoethanol, 1 mM HEPES buffer, and 1X non-essential amino acid solution (Gibco)). Cells 
were then plated in 96-well plates at 50,000 or 10,000 cells / well concentration and treated with 
0.01 to 10 ng/ml SIINFEKL peptide with or without 50 µg/ml of DC-MVs (as determined by 
protein content). After three days of culture, T cells were collected, washed, and stained with 
anti-CD8α, anti-CD25, and DAPI similarly to the procedure outlined above. 
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Adoptive Cell Transfer 
 OVA-specific, Thy1.1+ OT-I CD8α+ T cells were obtained as described above using the 
negative selection kit and adoptively transferred into naïve C57BL/6 mice via tail vein injection 
of 5 x 10
5
 cells. One day after transfer mice were immunized with SIINFEKL peptide (10 µg per 
mouse) with or without DC-MVs (250 µg protein per mouse). After 5 days, blood samples were 
obtained using submandibular bleeds and red blood cells removed via ACK lysis to yield 
peripheral blood mononuclear cells (PBMCs). Samples were processed for flow cytometry by 
washing, blocking CD16/32 Fc receptor, and staining with anti-CD8α, anti-Thy1.1, and in some 
cases anti-PD-1 fluorescently-labeled antibodies. Cells were then resuspended in FACS DAPI 
solution and examined via flow cytometry. In order to examine memory recall, mice were 
boosted with 100 µg OVA on day 26 after primary immunization and responses analyzed once 
more by analyzing frequency of Thy1.1+ CD8 T cells among PBMCs on day 33. 
 
Therapeutic Tumor Study 
 2 x 10
5 
B16F10 OVA melanoma cells were inoculated subcutaneously into the flank of 6- 
to 8-week old C57BL/6 mice and allowed to establish tumors. Prime immunization was 
performed with 10 µg of SIINFEKL with or without 250 µg of (MPLA)DC-MVs on day 10 and 
compared to PBS control. On day 17, PBMCs were stained with H2-K
b
-SIINFEKL tetramer 
(MBL International) and anti-CD8α and analyzed via flow cytometry for frequency of OVA-
specific T cells. Study endpoints (tumor diameter > 15 mm, large ulceration, or moribund state) 
were used to establish overall survival. 
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Statistical analyses 
For animal studies, mice were randomized to match similar average volume of the 
primary tumors and all procedures were performed in a non-blinded fashion. Statistical analysis 
was performed with Prism 6.0 software (GraphPad Software) by one-way or two-way ANOVA 
with Tukey’s multiple comparisons post-test. Statistical significance is indicated as *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001. 
 
 
3.4 Results and Discussion 
Generation of DC-MVs 
 Dendritic cell surface proteins interact with T cells promoting their activation and 
proliferation, but the use of ex vivo generated DC vaccines is laborious and expensive [9]. We 
aimed to utilize the membrane preparation techniques developed in our lab to generate dendritic 
cell membrane vesicles (DC-MV), which could be prepared more easily and utilized as an off-
the-shelf product. Our studies focused on the use of murine bone marrow, extracted from the 
tibiae and femurs of C57BL/6 mice and differentiated into dendritic cells through the use of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) as described before [8]. Immature 
dendritic cells were collected from the supernatant of the culture and placed in separate dishes to 
be further activated. Similar cell preparation can be achieved by isolating monocytes from 
human patients and differentiating and activating the ex vivo [10]. 
 Monophosphoryl Lipid A (MPLA) has been proven to be a strong dendritic cell activator 
in the past, thus it was chosen as the immunostimulant for DC maturation [11]. Cells were 
cultured overnight in the presence of MPLA along with untreated cells to be used as a negative 
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control. Two MPLA-treated populations were prepared based on their adherence to treated 
flasks: suspended or loosely attached cells dissociated via pipetting (MPLA-S) and fully attached 
cells further treated with Accutase and removed with a cell scraper (MPLA). Untreated cells 
consisted mostly of the suspended and loosely adherent cells so the two populations were 
combined (NO TX). Next, the harvested cells underwent freeze-thaw lysis and mild probe-tip 
sonication. Fractionation was achieved through centrifugation and individual fractions (whole 
cell, debris, mitochondria, cytosol, and membrane) were analyzed via Western Blot analysis for 
the level of expression and enrichment of T-cell-activation ligands CD80 and CD86 (Fig. 3-2A, 
top and middle panels). Specifically, CD86 expression increased within the plasma membrane 
preparations following MPLA treatment (lanes 10 and 11) compared to the untreated controls 
(lane 9). Additionally, the higher intensity of the CD86 band and the lower intensity of the 
cytochrome c band within the membrane fraction compared to the whole cell lane (lane 1) 
demonstrate proper isolation of mature dendritic cell plasma membranes for further use (Fig. 3-
2A, bottom panel). 
 
DC-MVs can bind antigen peptide 
 Our lab has shown in the past that tumor cell membranes can be prepared into 
nanoparticles coated with polyethylene glycol (PEG) layer, which exhibited efficient lymph node 
draining, dendritic cell uptake, and T cell activation capabilities. To utilize this technology 
further, we have prepared DC-MVs in a similar manner through the freeze-thaw and sonication-
based cell lysis, calcium-driven membrane aggregation and separation, and finally PEGylation 
through the post-preparation DSPE-PEG insertion. These DC-MVs were then ready for loading 
of the antigen of interest onto the particle surface and use in subsequent studies (Fig. 3-1). 
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Figure 3-2. DC-MV characterization.  
A. Dendritic cells were left untreated or pulsed with MPLA to promote maturation. Loosely 
adherent cells were harvested via pipetting (MPLA-S), while adherent cells were detached with 
Accutase and scraped (MPLA). For untreated cells, the two preparations were combined for 
analysis (NO TX). Cell were fractionated and analyzed via Western Blot for expression of CD80, 
CD86, or cytochrome c (cyt c). B. DC-MVs were prepared and incubated with SIINFEK(FITC)L 
peptide to promote loading. After purification, peptide retention was analyzed by fluorescence. 
 
 We focused on the use of peptide with the amino acid sequence SIINFEKL, which is a 
CD8α+ T cell immunogenic epitope from model antigen ovalbumin (OVA). First, we examined 
the ability to load SIINFEKL peptide onto DC-MVs by utilizing LC/MS, but extraction of the 
peptide from this complex formulation proved difficult (data not shown). Back-up approach 
involved the use of labeled peptide with covalently bound fluorophore (FITC) to the lysine 
amino acid of the peptide (SIINFEK(FITC)L), which has been shown in the past to effectively 
bind to MHC-I [12]. We generated (MPLA)DC-MVs and unstimulated DC-MVs and incubated 
them with SINFEK(FITC)L at various membrane protein concentrations followed by desalting 
column washing capable of removal of 99.98% of free peptide (data not shown). Importantly, 
different mouse strains express varying MHC-I alleles, prompting us to generate (MPLA)DC-
MVs from C57BL/6 (H-2K
b
, H-2D
b
) and BALB/c (H-2K
d
, H-2D
d
, H-2L
d
), where only H-2K
b
 is 
capable of binding SIINFEKL [13]. The results demonstrate that SIINFEKL loading onto DC-
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MVs is dependent only on the vesicle concentration and independent on the state of activation 
(MPLA-treated vs immature) and the MHC-I haplotype (Fig. 3-2B). This outcome suggests that 
the peptide is loaded onto the particle through electrostatic interactions indicating that DC-MVs 
may function as effective delivery vehicles. 
 
DC-MVs active live DCs in vitro  
Exosomes and naturally-produced membrane vesicles had been known to carry secondary 
messengers and transduce cell-to-cell signals [14, 15]. We sought to determine if the artificially 
produced DC-MVs can serve to activate live dendritic cells in vitro. We employed commonly 
used maturation assay, where cultured BMDCs are pulsed with various formulations and 
analyzed for expression of activation markers, CD40 and CD80, via flow cytometry. 
Importantly, (MPLA)DC-MVs but not immature DC-MVs have led to upregulation of both 
activation markers, suggesting a potential role of this platform as not only a vehicle for peptide 
delivery, but also as an immunostimulatory adjuvant (Fig. 3-3A,B). Interestingly, (MPLA)DC-
MVs but not MPLA alone served to upregulate CD80, which can directly bind to CD28 on T 
cells leading to enhanced proliferation (Fig. 3-3B).  
These data support a hypothesis where DC-MVs may bind peptides non-specifically 
through electrostatic interactions and efficiently deliver them to the lymph nodes while providing 
a vehicle and adjuvant function. We had also considered another mechanism through which DC-
MVs may activate and promote T cell proliferation: antigen peptides may bind directly to the 
MHC-I surface protein providing binding site for antigen-specific T-cell receptor (TCR) and 
together with activation surface receptors CD80 and CD86 may function as a nano-sized antigen 
presenting platform analogous to fully mature dendritic cells. These approaches had been studied 
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in the past and provide attractive alternative methods to standard vaccination [16, 17]. The next 
set of studies was used to tease out the appropriate mode of action of our DC-MV therapy. 
 
 
 
Figure 3-3. BMDC activation using DC-MVs.  
BMDCs were cultured with non-activated DC-MVs and (MPLA)DC-MVs and examined for 
expression maturation markers CD40 (A) and CD80 (B) via flow cytometry 
 
In vitro T cell proliferation 
 To examine the ability of the DC-MVs to directly interact with T cells and promote their 
activation and proliferation through TCR and CD28 engagement, we focused on the commonly 
used CFSE dilution assay [18]. Briefly, OVA-specific CD8α+ T cells were isolated from the 
spleens of OT-I transgenic mice, labeled with the CFSE fluorescent dye, and co-cultured with the 
MPLA-treated or unstimulated DC-MVs in the presence of SIINFEKL. Using the standard 
50,000 cells/well seeding density, we observed that SIINFEKL alone led to strong proliferation 
across the 10 to 0.1 ng/ml peptide concentration range, while DC-MVs or (MPLA)DC-MVs had 
no additional effect (Fig. 3-4A). However, looking at the relative number of cells surviving 
through the three day culture, (MPLA)DC-MVs followed by DC-MVs performed better than the 
SIINFEKL control (Fig. 3-4B). Finally, we examined the proliferating T cells for the expression 
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of CD25, a subunit of the IL-2 receptor and a late marker of TCR-dependent T cell activation. At 
10 to 1 ng/ml peptide concentration over 50% of proliferating T cells were expressing CD25 
after co-culture with DC-MVs compared to approximately 15% when stimulated with 
SIINFEKL alone (Fig. 3-4C). Importantly, at the highest concentration, (MPLA)DC-MVs 
outperformed immature DC-MVs suggesting increased efficacy following adjuvant treatment. 
 Taken together, these results have led us to speculate that the introduction of SIINFEKL 
peptide alone to the OT-I T cell culture leads to peptide binding and presentation in the context 
of MHC-I on the T cell surface itself. This causes swift T cell cross-priming and eventual cross-
killing, which is demonstrated by low surviving cell counts and low CD25 expression suggesting 
lack of prolonged activation. To test this hypothesis, we performed the CFSE dilution assay 
again, but this time utilizing lower seeding OT-I T cell density (10,000 cells/well; or 5-fold 
decrease from before) in order to minimize cell-to-cell interactions. (MPLA)DC-MVs have led 
to enhanced T cell proliferation at 10 and 1 ng/ml peptide concentrations compared to the 
SIINFEKL alone (Fig. 3-4D). Importantly, the number of surviving T cells and surface 
expression of CD25 was markedly increased due to the presence of (MPLA)DC-MVs (Fig. 3-
4E,F). Based on these results, we suspect that the activation markers present on DC membranes 
can effectively engage and enhance T cell proliferation in vitro, prompting us to test this 
formulation in vivo. 
 
Characterization of DC-MV mechanism of action 
The previous in vitro data indicated that DC-MVs may directly interact with T cells and 
promote their healthy proliferation. While this may be possible in the controlled and simple cell 
culture conditions, it may be difficult to achieve within the physiological complexity of the body. 
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As a result, we set out to determine if DC-MVs can deliver cargo and then directly activate 
antigen presenting cells by screening this effect in vivo. Considering potential low 
immunogenicity of our platform and controlling for mouse to mouse variability, we set off to 
utilize adoptive cell transfer of OT-I T cells to provide a basal, equivalent antigen-specific T cell 
population within each animal. 
Immunization was administered one day after adoptive cell transfer of 5 x 10
5
 OT-I 
CD8α+ T cells and blood samples were analyzed for Thy1.1+ T cells on day 5. Formulations 
were prepared as before, by incubating antigen peptides with DC-MVs at 37°C allowing for 
surface loading, but this time no column purification was performed in order to allow equivalent 
10 µg of peptide to be delivered across all groups. Taking previous results into consideration, we  
 
 
Figure 3-4. T cell proliferation in presence of DC-MVs.  
OT-I T cells were incubated with SIINFEKL peptide alone or in the presence of non-activated 
and (MPLA)DC-MVs at two cell amounts of 50,000 cells/well (panels A-C) or 10,000 cells/well 
(panels D-F) for three days and analyzed via flow cytometry. A and D. Average percentage of 
proliferated T cells is shown. B. and E. Relative count of live T cells was determined within the 
CD8α+ population. D and F. Percentage of T cells expressing CD25 activation marker is shown. 
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suspected that only ~1.3% or ~130 ng of peptide would be associated with the particles and aided  
with trafficking to the lymph node, while the remainder was free to interact with serum proteins  
and cell surfaces. However, the (MPLA)DC-MVs efficiently delivered the peptide and led to 
OT-I T cell expansion improvement over the soluble SIINFEKL controls regardless of the mouse 
strain used, reinforcing lack of necessity for matched MHC-I alleles (Fig. 3-5). Importantly, 
C57BL/6- and BALB/c-sourced MPLA-activated MVs have demonstrated improvements in T 
cell activation compared to unstimulated DC-MVs (P = 0.035 and P = 0.0002, respectively), 
verifying previous results suggesting that the maturation state of BMDCs prior to harvesting 
their membranes plays a role in their function. These experiments suggest that the initial 
hypothesis of LN delivery along with immunostimulatory functions may be correct and that DC-
MVs may serve as potential peptide vaccine vehicles for cancer immunotherapy. 
 
Figure 3-5. T cell proliferation in vivo following ACT.  
Mice were adoptively transferred with 500,000 OT-I Thy1.1+ CD8α+ T cells and immunized the 
following day with SIINFEKL peptide with or without the DC-MVs. After 5 days, PBMCs were 
collected and examined for the fraction of CD8α+ T cells expressing Thy1.1. 
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Therapeutic immunization against melanoma 
 The aim of this vaccination platform focused on enhancement of T cell activation and 
proliferation in vivo using peptide-based approaches. We examined this function by employing 
murine B16F10 OVA melanoma, expressing model antigen ovalbumin. In previous studies, we 
observed that low levels of endogenous, OVA-specific responses are generated upon tumor 
inoculation and that they can be boosted through vaccination approaches (data not shown). 
B16F10 OVA tumors were established through subcutaneous injection of 2 x 10
5
 cells in the 
flank of mice, immunized on day 10, and examined for CTL responses on day 17 (Fig. 3-6A). 
 OVA-specific T cell responses were analyzed via tetramer staining assay focusing on 
antigen-specific CD8α+ T cell population among peripheral blood mononuclear cells (PBMCs) 
(Fig. 3-6B). Naïve animals were used to establish the staining background, while tumor-bearing 
PBS-treated mice showed low level of baseline responses against ovalbumin. SIINFEKL alone 
treatment had no effect on increasing the endogenous responses. Importantly, co-administration 
of SIINFEKL with (MPLA)DC-MVs has led to generation of strong T cell responses in two of 
the five animals, and while not statistically significant (P = 0.08 vs PBS and P = 0.22 vs 
SIINFEKL), suggests an overall trend in enhanced efficacy. However, we did not observe any 
improvement in terms of decreasing tumor growth or enhancing overall survival (Fig. 3-6C).  
The parental B16F10 melanoma model is difficult to treat due to quick progression and 
often requires combination therapy approaches, thus administration of DC-MVs on day 10 may 
not have been sufficient, even with the presence of foreign antigen OVA [19, 20]. Additionally, 
based on the response rate to the DC-MV therapy that we have observed, we speculate that this 
approach may not be suitable for initial activation of CTLs, but rather boosting the responses 
which are already present. Specifically, we suspect that the two mice that have had high levels of  
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Figure 3-6. T cell proliferation in tumor-bearing mice.  
A. Mice were inoculated with B16F10 OVA melanoma and immunized 10 days later with 
SIINFEKL or (MPLA)DC-MV-SIINFEKL. B. OVA-specific T cell population was analyzed 
among CD8α+ PBMCs 7 days after immunization. C. The overall survival of the mice is shown. 
 
OVA-specific T cells were most likely to already have elevated responses at the time of 
vaccination due to the presence of the OVA-expressing tumor. Further pursuit of this therapy 
would have to focus on prior examination of existing T cell responses with the goal to engage 
and activate them prompting expansion to therapeutic levels. 
 
Memory recall response of ACT T cells 
 Up and coming therapies had focused on adoptive cell transfer (ACT) of antigen-specific 
T cells and range from the isolation and expansion of tumor infiltrating lymphocytes (TILs) to 
genetically engineering chimeric antigen receptor (CAR) T cells [21-23]. While providing strong 
responses and therapeutic effects against cancer in early clinical trials, these approaches are 
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associated with potential safety concerns, which prevent administration of high doses of T cells. 
Importantly, efficacy and long-term remission in cancer patients is associated with maintenance 
and survival of the adoptively transferred T cells and, in cases of relapse, patients will sometimes 
undergo reinfusion of antigen-specific CTLs [24]. As demonstrated in our melanoma tumor 
model, DC-MV approach may be capable of expansion and maintenance of tumor-specific T 
cells, prompting us to test if it can be used together with ACT therapy. 
 Mice were adoptively transferred with 5 x 10
5
 OT-I T cells and immunized the following 
day with SIINFEKL peptide (10 µg) with or without CpG adjuvant or in the context of DC-MVs 
and varying concentrations of (MPLA)DC-MVs (Fig. 3-7A). We observed strong level of T cell 
proliferation at all (MPLA)DC-MV doses measured by assessing presence of Thy1.1 marker on 
CD8α+ T cells among PBMCs, suggesting effective activation of OVA-specific CTLs (Fig. 3-
7B). In comparison, immature DC-MVs and SIINFEKL peptide alone failed to promote T cell 
maintenance over the five day period. SIINFEKL combined with immunostimulatory molecule, 
CpG, was effective at increasing T cell proliferation and served as a positive control. We have 
also focused on examining Programmed Death 1 (PD-1) receptor expression on the activated 
OVA-specific T cells. (MPLA)DC-MVs led to PD-1 upregulation in a dose-dependent manner 
suggesting strong levels of activation at high doses (Fig. 3-7C). In order to examine the level of 
T cell maintenance over time and the formation of memory T cell responses, we administered a 
boost immunization using 100 µg of soluble OVA. We observed that while SIINFEKL + CpG 
generated a consistent recall response resulting in approximately 40% of OVA-specific T cells, 
(MPLA)DC-MVs showed a broad range of memory recall characterized by a few very strong 
(~60%) but predominantly low (~15%) T cell expansion across the varying doses (Fig. 3-7D). 
Importantly, these responses showed correlation to the results from the primary immunization, 
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where well-expanding, PD-1
low
 responders demonstrated greatest level of proliferation following 
the boost. These data suggest that the level of T cell activation by the DC-MV formulation 
requires further optimization and fine-tuning to prevent over-activation of ACT CTLs and the 
potential for anergy, while at the same time demonstrating promise for prominent activation and 
maintenance of the antigen-specific T cell population. 
 
 
 
Figure 3-7. Memory recall responses. 
A. Mice were immunized were adoptively transferred on day -1 and immunized on day 0 with 
SIINFEKL with or without DC-MVs. Boost immunization of 100 µg soluble OVA was used to 
determine memory response. B. ACT T cell expansion was determined 5 days post-treatment via 
%Thy1,1+ CD8α+ T cells among PBMCs. C. PD-1 expression was examined on OVA-specific 
T cells. D. Memory responses of expanded OT-I ACT T cells after 100 µg OVA administration 
are shown. Mean ± SEM are shown. 
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3.5 Conclusions 
 This study has focused on generation and characterization of cell membrane vesicles 
from activated dendritic cells to function as peptide-based vaccine vehicles. We have 
demonstrated that (MPLA)DC-MVs have strong dendritic cell maturation capabilities and that 
they can effectively interact with peptide-pulsed OT-I T cells leading to strong proliferation and 
maintenance in vitro. In addition, in vivo administration of the SIINFEKL peptide along with 
(MPLA)DC-MVs allowed for expansion of adoptively transferred OT-I T cells and in some 
cases generation of strong memory T cell responses. Finally, mice bearing OVA-expressing 
tumors were immunized with SIINFEKL and (MPLA)DC-MVs leading to expansion of antigen-
specific T cells, but therapeutic effect has not been shown. Further studies will focus on 
determining optimal in vivo T cell activation and proliferation in order to generate therapeutic 
level of responses. The potential use for this technology would revolve around promoting T cell 
memory in adoptive cell transfer therapies or boosting existing self- and neo-antigen approaches 
to combat cancer. 
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Chapter 4: Nanoparticle Analysis by Flow Cytometry for Characterization and Prediction 
of Responses In vivo 
 
4.1 Abstract 
 Nanoparticles had been utilized since the advent of liposomes several decades ago due to 
their favorable pharmacokinetic properties. While great advances had been made in the 
characterization of these formulations, most of them focused on bulk analysis without closely 
examining features of each particle. Recent advances in flow cytometric analysis allow for the 
examination of individual nano-sized particles prompting us to adopt and further develop this 
technique. In these studies, we demonstrate setup of the MoFlo Astrios cytometer for the 
characterization lipid-based nanoparticles by analyzing incorporated fluorophores as well as 
probing the surface display of antigens with antibodies. Ultimately, thorough analysis of cell 
membrane vesicles derived from cancer and dendritic cells will assist in understanding and 
proper optimization of these formulations for further use in cancer immunotherapy. Meanwhile, 
additional studies utilized hepatitis C virus antigen E2 incorporation into varying nanoparticle 
formulations and examined correlation with murine immune responses following vaccination. 
The results showing similar broadly neutralizing antibody binding to E2-his and E2c-his 
nanoparticle constructs via flow cytometry provided explanation for activity shown via in vitro 
neutralization assay. Taken together, we have demonstrated effective adaptation of nanoparticle 
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flow cytometry methodology and analysis of lipid-based nanoparticle vaccine formulations 
establishing foundation for further work with cell membrane vesicles. 
 
4.2. Introduction 
Nanoparticles have been widely utilized for various therapeutic approaches by providing 
major benefits such as limiting the systemic drug availability, providing controlled release, or 
enhancing drug accumulation at the site of action [1, 2]. Specifically, the use of nanoparticles for 
vaccination has been greatly exploited in recent years, as they can effectively encapsulate 
antigens and adjuvants, protect the cargo from degradation, and, due to their size, efficiently 
traffic to the local lymph nodes [3]. As these formulations may often mimic pathogenic 
architecture, the surface presentation and appropriate density of antigens may direct generation 
of potent antibody responses due to cross-linking of B cell receptors conveying strong activation 
[4, 5]. 
 Standard formulation characterization includes determination of particle size, surface 
charge (zeta potential), and polydispersity [6]. Recently, nanoparticle tracking analysis (NTA) 
technology has allowed for further insight into size as well as fluorescence features of 
formulations by characterizing individual particles [7]. In addition, various types of electron 
microscopy (EM) may be used to explore detailed surface structure (scanning EM) or even 
visualize individual protein antigens (cryo-EM) [8]. Determining encapsulation amount of 
antigens and adjuvants within simple nanoparticle formulations with limited number of 
components can be achieved using multiple techniques such as bicinchoninic acid assay (BCA), 
Coomassie staining, or high-pressure liquid chromatography (HPLC). While quantification of 
absolute amount of antigen present within the formulation is necessary, it is also important to 
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determine the amount of biologically active, or in the case of vaccines, immunogenic protein 
cargo [9, 10]. Many biologic-based nanoparticle approaches utilizing exosomes or plasma 
membrane preparations may be quite difficult to analyze due to sample variability and presence 
of strong background in these highly complex structures. Due to recent technological advances, 
flow cytometry has been adapted to be used for high throughput and effective analysis of these 
types of nano-sized formulations [11-14]. These studies had focused on enumeration of 
nanoparticles within various biological samples and detecting expression of activation markers 
on cell-secreted exosomes 
Exosomes can effectively be isolated from patients or tissue culture and examined for 
surface presence of particular markers, such as MHC-I, with the use of antibody staining [15]. 
We sought to establish this technique to allow for close analysis of membrane vesicles generated 
in our lab from tumor cells and dendritic cells for cancer vaccination. Expression of specific cell-
surface proteins on the outside of the particles would assist in their designated function and the 
use of nanoparticle flow cytometry would provide the necessary confirmation and aid in protocol 
optimization. For the tumor cell membrane vaccine, surface presence of ovalbumin (OVA, 
model exogenous antigen) would confirm its incorporation and hint at potential ability of these 
particles to elicit OVA-specific humoral responses. Recent reports demonstrate that Fas ligand 
and PD-L1 expression on membrane vesicles shed by the tumor cells may lead to decreased T 
cell function, thus assessing our formulations for presence of these molecules would provide 
further insight [16-18]. In terms of the dendritic cell platform, expression of co-stimulatory 
markers, CD80/86, would allow to screen for optimal DC activation, harvest, and particle 
preparation protocol. At the same time, we had hoped to utilize this approach to aid other 
research avenues, thus we focused on analysis of lipid nanoparticle-based vaccine formulations.  
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In particular, broadly neutralizing antiviral antibodies, providing protection against 
different strains of one virus, have been sought after for a long time, and while their 
identification and characterization have been achieved, inducing production of these antibodies 
has been challenging [19]. Lack of effective vaccines against prevalent viruses, such as Hepatitis 
C Virus (HCV), Human Immunodeficiency Virus (HIV), and even influenza, stems from the 
highly mutagenic nature and presence of numerous variable regions on the surfaces of these 
pathogens. We hypothesized that proper preparation and orientation of the antigen on the particle 
surface, demonstrated by the ability of binding known broadly neutralizing antibodies in vitro, 
will allow for the recognition and production of broadly neutralizing antibodies against those 
epitopes in vivo. 
In this study, we demonstrate the flow cytometry setup, which has allowed for single 
particle analysis and examination of antigen loading efficiency in model experiments. 
Importantly, the use of this technique has allowed us to confirm antigen presence on the surface 
of tumor membrane vesicles. Finally, we were able to examine different lipid-based nanoparticle 
vaccines against HCV and screened them with a panel of monoclonal antibodies with broadly 
and non-broadly neutralizing capabilities. To our knowledge, this is the first time that flow 
cytometry approach has been use to examine antigen presentation and configuration on 
synthetically generated nanoparticles as opposed to exosomes shed by cells. Correlation of this 
data with responses in vivo would provide the possible use of this technique for screening of 
future vaccine formulations prior to in vivo administration saving on labor, costs, and animal use. 
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4.3. Materials and Methods 
Nanoparticle preparation 
Multilamellar vesicles (MLVs) and interbilayer cross-linked multilamellar vesicles 
(ICMVs), the lipid-based formulations utilized in these studies, were prepared as previously 
reported [20]. In short, lipid film generated by drying 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) 
butyramide] (MPB) in a 1:1 ratio was rehydrated with aqueous 10 mM bis-tris propane buffer by 
vortexing for 10 seconds every 10 minutes for 1 hour. Next, particles were probe-tip sonicated 
(40% intensity setting on 125W/20kHz sonicator) to generate unilamellar vesicles. Addition of 
33 mM CaCl2 and 2.4 mM dithiothreitol (DTT) allowed for fusion and molecular stapling of the 
lipid bilayers during 1 hour incubation at 37°C. Next, particles were washed twice with ddH2O 
and incubated with 10 mg/ml polyethylene glycol-thiol (PEG(2K)-SH) to allow surface 
PEGylation for 30 minutes at 37°C. Finally, particles were washed twice more with ddH2O and 
resuspended in PBS.  
For the HCV formulations, ICMVs were produced as described above whereas NTA 
ICMV synthesis was performed by incorporation of 2% 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-
1-carboxypentyl)iminodiacetic acid)succinyl] nickel salt (DOGS NTA) lipid within the lipid 
film. HCV E2 constructs were kindly provided by Dr. Mansun Law from The Scripps Research 
Institute. 
 Cell membrane nanoparticles were generated from cancer cell lines (B16F10 OVA or 
CT26 cell line) by freeze-thaw cycling, sonicating, and removing large debris via centrifugation. 
Then, 20 mM calcium chloride was used to aggregate membrane fractions (adjusted to 6 mg/ml 
of total protein), followed by tabletop centrifugation for washing, and post-preparation insertion 
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of DPSE-linked polyethylene glycol (5kDa, Laysan Bio) and removal of calcium via EDTA 
treatment. Particles were passed through Zeba desalting column in order to remove any free 
DSPE-PEG and calcium-bound EDTA. 
 
Fluorophores and antibodies 
Nanoparticles were labeled with a Di family of dyes including 3,3'-
Dioctadecyloxacarbocyanine Perchlorate (DiO, excitation/emission = 488/520 nm), 1,1'-
Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate (DiI, excitation/emission = 
530/580), 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate 
Salt (DiD, excitation/emission = 600/660 nm), and (1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindotricarbocyanine Iodide (DiR, excitation/emission = 600/780 nm). 
AlexaFluor647-NHS was utilized to fluorescently label ovalbumin (Worthington). 
Allophycocyanin (APC) and Phycoerythrin (PE) were prioritized as the fluorophore conjugates 
for the secondary antibodies due to their strong fluorescence output, or brightness. 
 Rabbit anti-OVA primary IgG (Abcam) and anti-rabbit IgG secondary antibody linked to 
APC (Thermo) were used for studies focused on ovalbumin surface presentation. Monoclonal 
human HCV specific primary antibodies were kindly provided by Dr. Mansun Law. Secondary 
antibody utilized was anti-human IgG linked with PE (eBioscience). 
 
Antibody staining 
Particles were freshly prepared and resuspended in FACS buffer (1% bovine serum 
albumin in PBS, w/v) to allow for blocking of nonspecific interaction. Then primary antibody 
was added to the solution of each particle and incubated over night at 4°C. Samples were washed 
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once with FACS buffer by centrifugation at 20,000 x g for 45 minutes with a 4°C temperature 
setting. Particles were then resuspended in a secondary antibody FACS buffer solution and 
incubated for 1 hour on ice. Samples were then washed two more times with FACS buffer. For 
bulk analysis, samples were transferred to 96-well black opaque plates and read using a plate 
reader (BioTek). Finally, samples were transferred to individual 5 ml round-bottom tubes and 
refrigerated prior to analysis by flow cytometry.  
 
Flow cytometry 
 Flow cytometric analysis was performed using MoFlo Astrios EQ (Beckman Coulter) 
equipped with the Dual-PMT (Photomultiplier Tube) Forward Scatter Upgrade with M1 and M2 
masks. 488 nm laser forward scatter detector was used for triggering events and relatively low, 
but noise-eliminating, threshold level was utilized (0.002% off of 300 voltage with 100% laser 
power). Further side scatter gating was utilized to eliminate aggregates within samples to 
generate monodisperse single-particle populations within the fluorescence plots. Results were 
analyzed by FlowJo software. 
 
Animal Studies 
 6- to 8-week old female C57BL/6 mice were immunized with E2-his and E2c-his NTA 
ICMV formulations using a prime / boost / boost approach with 10 / 5 / 5 µg of antigen and 1.0 / 
0.5 / 0.5 µg MPLA, respectively, and were administered subcutaneously at the tail base. Each 
immunization was given three weeks apart (days 1, 21, 42), whereas sera samples were also 
collected three weeks apart starting one day prior to first boost immunization (days 20, 41, 62). 
Sera titers were examined via ELISA assay, where E2 antigen adhering to lectin-coated plate 
91 
 
was utilized to capture antigen-specific murine antibodies. After washing, samples were stained 
with anti-mouse IgG HRP-linked secondary antibody, washed further, and then developed to 
determine overall antibody titers. Neutralization assay was performed as described before [21], 
but this time incubating cells with viral pseudo particles with or without immunized murine sera 
for 6 hours and allowed for infection to take place over 72 hours. 
 
Stability Studies 
 ICMV samples tagged with DiO and encapsulating AF647-OVA were centrifuged 
(20,000 x g, 45 minutes) and resuspended in plain RPMI or RPMI containing 10%, 50%, or 90% 
of FBS. Samples were then incubated while shaking at 37°C for 24 hours and diluted with FACS 
buffer to be directly run on the flow cytometer with the appropriate media controls.  
 
 
4.4. Results and Discussion 
Nanoparticle flow cytometry setup 
Flow cytometry has been utilized for surface and intracellular marker analysis allowing 
for high-throughput characterization of mixed cell populations. Utilization of this technique for 
nanoparticle characterization would provide new information and allow for increased work 
efficiency. However, due to the difference in size between cells and nanoparticles spanning a few 
orders of magnitude, a few considerations must take place. Most importantly, triggering the 
instrument to record an event taking place becomes challenging due to the particle size (~200 nm 
compared to the 488 nm laser) and the low light-scattering characteristics of tiny lipid-based 
structures.  
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In order to address these issues, we utilized MoFlo Astrios cytometer equipped with 
particle analysis module and started off by greatly decreasing the trigger threshold until the 
detection of non-specific noise occurred even when no sample was being analyzed (Fig. 4-1A). 
Next, running filtered PBS has shown low levels of background noise, which could be 
distinguished from the strong machine noise by plotting the signal from two forward scatter 
detectors against each other (Fig 4-1A). By next raising the threshold, the machine noise was 
eliminated and running nanoparticle sample generated a distinctly grouped population (Fig. 4-
1B). In addition, the inability to detect very small particles within the sample may skew our 
overall results, but considering the high monodisperisity of our formulation (data not shown), we 
expected to obtain a proper representation. 
 
Detection of fluorescence signal 
 Once the particles were effectively detected by the flow cytometer we sought to detect 
the fluorescence signal within our formulation and determine the analytic dynamic range. 
Throughout all of our experiments we focused on the use of lipid-based nanoparticle 
formulations generated by previously-reported methods from our lab [20, 22]. Briefly, particles 
were prepared through hydrating lipid films to generate multi-lamellar vesicles (MLVs), 
sonicated, and then fused in a controlled manner through the addition of calcium chloride. 
Addition of dithiol linker allowed for stapling of the multiple lipid bilayers due to presence of 
maleimide-functionalized lipids and stabilizing post-synthesis PEGylation generated interbilayer 
cross-linked multilamellar vesicles (ICMVs). 
 First, ICMVs were formulated with the addition of a lipid-based dye (DiO, 
excitation/emission = 488/520) into the lipid film prior to hydration, capable of incorporation  
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Figure 4-1. Forward vs side scatter FACS plots showing nanoparticle detection.  
A. Machine noise can be eliminated by increasing the threshold on the forward scatter detector. 
B. Nanoparticles can be detected with reasonably low background in the PBS control alone. 
 
into the bilayer. Analysis of these particles via flow cytometry has demonstrated a clear 
separation from the unlabeled, blank ICMVs (Fig. 4-2A). Importantly, the DiO-labeled particles 
generated a single peak with no events registering near the unlabeled population. Because of this, 
we feel confident that addition of the DiO tag to all of our future analyses will provide a critical 
quality control step, ensuring that the events that we analyze represent true single-particle 
populations and exclude any potential particulate contamination. 
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 The next step was to demonstrate that the fluorescence signal is dependent on the amount 
of fluorophore present, thus ensuring a dose-dependent dynamic range. ICMVs were hydrated 
with aqueous solution containing 0, 25, or 100 µg of ovalbumin fluorescently labeled with 
AlexaFluor647 (AF647, excitation/emission = 600/660). Cytometric analysis demonstrated 
discernable peaks with median fluorescence intensity dependent on the amount of dye 
encapsulated (Fig. 4-2B). Taken together, these results have shown that nanoparticles can be 
labeled with lipophilic dyes and fluorescently-tagged cargo and analyzed within the dynamic 
range. 
 
 
 
 
Figure 4-2. Fluorescence detection in nanoparticles.   
A. Particles can be separated based on fluorescence from DiO loaded into lipid layers. B. 
Particles can be separated based on the amount of fluorescently-labeled protein encapsulated 
within the formulation. 
  
Detection of separate populations 
 Previous analysis has focused on comparing separate samples analyzed via flow 
cytometry, whereas we have aimed to utilize this technique for distinguishing and characterizing 
various populations within mixed samples. In order to establish our capacity to achieve that, we 
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have prepared MLVs labeled with previously utilized DiO, a different lipophilic dye (DiR, 
excitation/emission = 600/780), combination of both dyes (DiO and DiR), or no fluorophores at 
all (blank). As shown, separately ran samples have resulted in distinct populations present in four 
quadrants on the DiO vs DiR mean fluorescence intensity (MFI) FACS plots (Fig 4-3A). As 
noted in the far-right panel, there is a linear trend suggesting that particles incorporating greater 
levels of DiO also encapsulate greater amounts of DiR. Considering their multilamellar nature, it 
is expected for particles of various sizes and with various numbers of bilayers to incorporate 
varying amounts of the lipophilic dye. However, the amount of incorporation for both dyes 
should be proportional, which is what is seen in the last panel. 
 Most importantly, the bottom panel demonstrates that the mixture of the nanoparticle 
preparations within one sample can be easily separated (Fig 4-3B). As shown, the double DiO- 
and DiR-labeled particles retain the above-described pattern, but the level of fluorescence of 
individual dyes remains constant. These data strongly support the ability of this technique to 
identify and analyze fluorescence exhibited by individual nanoparticles. 
 
Nanoparticle FRET 
Fluroescence Resonance Energy Transfer (FRET) is a valuable technique utilized to 
determine the proximity of two fluorophores: donor and acceptor [23]. Samples are excited at a 
wavelength which can be absorbed by the donor and then emitted at a higher wavelength or 
directly transferred to the acceptor, which will then emit a photon at an even greater wavelength. 
Due to requirement for sub 10 nm distances, this technique has been used for examining protein-
protein interactions, protein folding, as well as lipid membrane fusion and association. We had 
decided to determine if our flow cytometry method would be able to detect and analyze the  
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Figure 4-3. Detection of individual nanoparticles.  
A. Various fluorophores and fluorophore combinations can be used to label nanoparticle 
preparations. B. Physical mixture of fluorophore-labeled particles can be separated into distinct 
populations. 
 
FRET phenomenon providing insight into lipid membrane fusion and association on a single-
particle basis rather than with previously utilized bulk analysis [24]. 
We utilized DiO and DiI dyes, which act as donor and acceptor respectively and sought 
to determine if the physical mixture of the particles exhibits can be distinguished from one 
another (Fig. 4-4A). While it becomes very apparent that there are two distinct populations of 
DiO and DiI nanoparticles, incorporation of both dyes within the same formulation does not lead 
to detection of the signal within quadrant two of the scatter blot as seen before with DiO and 
DiR. In fact, the DiO + DiI particles exhibit decreased DiO fluorescence and enhanced DiI 
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signal. The FRET ratio, suggesting the relative amount of fluorescence transfer that takes place, 
was calculated, where ratio approaching 1 indicates complete transfer and ratio of approaching 0 
indicates lack of the FRET effect (Fig. 4-4B). We sought to establish the FRET efficiency (the 
FRET ratio expressed in percent form) via plate- and FACS-based assays, which led to 
somewhat consistent results (Fig. 4-4C). Taken together, the results indicate that fluorophore 
incorporation into the film or into the unilamellar vesicles prior to fusion allows for complete 
mixing and efficient fluorescence transfer. Further studies utilizing this technique could focus on 
the plasma membrane or endosomal membrane fusion events, which had been analyzed via bulk-
based approaches, but not via single-particle analysis to our knowledge. 
 
 
 
Figure 4-4. Analysis of FRET signal.  
A. Individual FACS plots demonstrate individual populations within particle mixtures. B. FRET 
ratio equation is shown. C. FRET efficiencies were calculated based on fluorophore 
incorporation method.  
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Antibody labeling of nanoparticles 
As discussed above, establishing a dynamic range in which the signal can be detected, not 
saturated, and correlated to the dye encapsulation efficiency is important for appropriate 
characterization. We generated nanoparticles incorporating six different amounts of OVA-
AF647, which demonstrated an increasing amount of fluorescence detected by the flow 
cytometric method (Fig. 4-5A). 
 The downstream goal of this study focuses on the antibody-based approach of this 
technique on probing the surface antigen amount and configuration (Fig. 4-5B). To demonstrate 
this, DiO-tagged ICMVs were generated containing varying amounts of unlabeled OVA (50, 
100, 200, and 400 µg initial hydration). As shown, the DiO content per particle remained quite 
consistent among the different formulations suggesting lack of aggregation and similar particle 
size (Fig. 4-5C). Analysis of the antibody binding capability, has demonstrated an increasing 
level of APC signal plateauing past the 200 µg formulation (Fig 4-5D). We suspect the binding 
to be limited due to increased incorporation of OVA on the inside of the particle, considering 
that the surface may already be protein-saturated at the 200 µg level. In addition, as the surface 
OVA protein increases in density, it may sterically hinder further antibody binding, resulting in 
the APC signal to become level. 
 Finally, as we sought to correlate these results to the bulk analysis, we utilized a plate 
reader approach for fluorescence detection. It was important to take into consideration that the 
nanoparticle preparation and the antibody staining process are quite extensive and may lead to 
unexpected loss through numerous centrifugation and pipetting steps. DiO incorporation was 
used to serve as a basis for the particle recovery from the overall protocol and thus utilized for 
normalization of the APC signal. The results demonstrate very similar trends, with the plateauing 
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effect seen at 200 µg of loaded OVA (Fig. 4-5E). Based on this data, the nanoparticle flow 
cytometry can effectively be correlated with the bulk plate reader-based analysis, while retaining 
the particle-by-particle measurement capacity. 
 
 
 
 
 
Figure 4-5. Nanoparticle surface antibody binding. 
 A. NanoFACS analysis of AF647 signal from ICMVs loaded with various amounts of OVA-
AF647. B. Schematic and histogram sample results depicting primary and secondary antibody 
nanoparticle staining. C. DiO MFI for particles loaded with various amounts of OVA. D. 
Antibody binding intensities analyzed by NanoFACS. E. Antibody binding intensities analyzed 
by plate-based approach. C and D depict particles that have (black filled circles) and have not 
(gray open circles) undergone the antibody staining protocol. 
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Detection of antigens on surface of tumor membrane vesicles 
 Tumor membrane nanoparticles can be used effectively for elicitation of immune 
responses as they can effectively traffic to the lymph nodes and be processed by the antigen-
presenting cells. In order to enhance the structural understanding of the membrane nanoparticles, 
we sought to determine surface display of a model antigen, OVA, constructed to contain a 
transmembrane domain. Additionally, successful binding of anti-OVA antibodies on the particle 
surface would suggest potential for B cell receptor activation in vivo. We have previously 
observed this effect following B16F10 OVA lysate immunization, where anti-OVA IgG 
responses were detected in mouse sera (data not shown). 
 We generated two species of nanoparticles from the lysates of two separate cell lines, 
B16F10 OVA and CT26. For the purpose of these studies, sonicated lysates contained nano-
sized (approx. 180 nm) vesicles with unmodified surface, whereas the PEG-NPs, were slightly 
smaller (approx. 130 nm) and were modified with surface 5 kDa polyethylene glycol (PEG) 
chains (data not shown). B16F10 OVA lysates and PEG-NPs were expected to express 
ovalbumin on the surface, while CT26 served as a negative control. 
 B16F10 OVA lysate vesicles bound more anti-OVA antibody compared to the CT26 
lysate, suggesting antigen-specificity-driven results (Fig. 4-6). In addition, PEG-NPs generated 
from B16F10 OVA cell membranes had higher percentage of OVA-positive vesicles and greater 
overall MFI compared to CT26 PEG-NPs. However, the drastic difference between B16F10 
OVA lysates and the PEG-NPs, suggests a markedly decreased OVA accessibility on PEG-NPs 
surface. Rather than antigen loss, we expect the PEG layer to play an important role in 
generating unfavorable interactions with antibodies and provide steric hindrance for the access to 
the binding site. These results correlate with our observations that PEG-NPs may not be ideal  
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Figure 4-6. NanoFACS analysis of OVA-expressing B16F10 land control CT26 lysates and 
PEG-NPs.  
A. Percentage of OVA-positive vesicles in the membrane preparations. B. Mean fluorescence 
intensity of OVA in membrane preparations. 
 
 
 
candidates for eliciting humoral responses against surface antigens in tumor-bearing mice 
immunized with this formulation, although they can lead to efficient CTL activation (data not 
shown). Taking all of these data together, we have demonstrated that antigen on the surface of 
membrane nano-vesicles can be detected by antibody binding and flow cytometric analysis on a 
particle-by-particle basis. Further focus can take into account expression of immunosuppressive 
ligands such as FasL and PD-L1 on tumor membrane vesicles or analysis of membranes sourced 
from other types of cells, such as dendritic cells. 
 
HCV E2 Antibody Screen 
  Demonstrating appropriate antigen surface display in vitro can allow for examination of 
potential antibody-generating responses in vivo. If done in a high-throughput manner, as in the 
case of flow cytometry, various formulations can be tested and optimized saving on the costs, 
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labor, and animal use involved with pre-clinical studies. To establish, whether our nanoparticle 
flow cytometry can be utilized for this purpose, we employed the use of two different particle 
systems: ICMV and NTA ICMV. ICMV platform was chosen for its ability to display antigen on 
their surface and stability, whereas the experimental NTA ICMV variant preparation method, 
exploiting NTA-tagged lipid interaction with his-tagged protein, allowed for enhanced loading 
capacity and directed surface display. 
 Hepatitis C virus (HCV) contains rapidly mutating variable regions, which act to generate 
antibody responses lacking broadly neutralizing characteristics. Removal of variable regions as 
well as proper antigen display is believed to direct antibody responses against constant regions, 
thus allowing for cross-strain activity. In order to test this approach and validate the ability of our 
nanoparticle formulations to bind to broadly neutralizing antibodies, we generated formulations 
displaying E2 viral membrane protein. Two constructs with or without the variable regions were 
utilized (E2 and E2c, respectively) in two variant forms each to contain or exclude the poly-
histidine tag. E2 and E2c were encapsulated in standard ICMVs, while his-E2 and his-E2c were 
incorporated into NTA ICMVs to allow for NTA-his interaction to promote surface binding. 
Once the particles were generated with the use of fluorescent dye (DiD), they underwent 
antibody staining process utilizing several conditions summarized in Table 1. Primary stain was 
set overnight at 4°C followed by washing, 1 hour secondary staining, further washing, and 
incubation on ice prior to sample analysis.  
Overall, we did not see extensive differences in the binding of antibodies to the particle 
surface (Fig. 4-7A). Surprisingly, NTA ICMVs, which had greater overall encapsulation 
efficiency as well as higher surface protein display (data not shown), did not exhibit greater 
antibody binding compared to standard ICMVs. We suspect that the potential tight packing of  
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Table 1. Antibody panel used for characterization of E2 protein-loaded ICMVs and NTA-
ICMVs. 
 
the protein may produce steric hindrance and prevent effective antibody binding. In addition, 
NTA-his interaction, which is expected to be the driving force for the antigen retention on the 
particle surface, is not particularly strong, thus prolonged incubation and multiple washes may 
lead to overall antigen loss during the staining process. 
 E2-his and E2c-his NTA ICMVs were tested in vivo by administration of prime 
immunization and two boost doses three weeks apart. Antibody responses were measured using 
standard ELISA approach demonstrating that E2-his had generated slightly increased overall 
humoral responses in weeks 6 and 9 (Fig. 4-7B). In addition sera obtained from both groups 
during week 9 were utilized in an in vitro neutralization assay, where HCV pseudo particles were 
incubated in cell culture with or without the sera antibodies. E2-his NTA ICMVs led to increased 
neutralization of the autologous H77 HCV strain compared to E2c-his, whereas both led to 
immune responses with mild neutralization activity against the heterologous UKN1b12.6 strain 
(Fig. 4-7C). 
 
104 
 
 
 
 
Figure 4-7. HCV NTA ICMV flow cytometry analysis.  
A. Fold-change in MFI over isotype antibody binding for ICMVs and NTA ICMVs is shown. B. 
E2-specific antibody titers for E2-his and E2c-his NTA ICMVs at weeks 3, 6, and 9 post-
immunization were measured from sera. C. Week 9 neutralization assay against autologous HCV 
strain (H77), irrelevant control (LCMV), or heterologous HCV strain (UKN1b12.6) was 
performed in vitro. 
 
 The animal data alone provides insight into the types of responses that are generated by 
these formulations. While both E2-his and E2c-his led to strong humoral responses, the presence 
of greatly immunogenic variable regions 1 and 2 on the E2-his construct may account for 
increased antibody titers and more effective autologous virus neutralization. We had expected 
that the lack of the variable regions on E2c would direct the responses towards more effective 
broadly neutralizing antibody production, but similar neutralization efficacy was seen. The 
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nanoparticle flow cytometry data supports these results, by demonstrating that both E2-his and 
E2c-his are capable of binding the broadly neutralizing antibodies AR3A and HCV1 to the same 
degree, thus validating the similar level of broadly neutralizing responses. Further work is 
currently underway to examine E2c ICMVs (Fig. 4-7A, green bars), which show promising 
display of the HCV1 epitope. We hope that these methodologies can be utilized in the future to 
demonstrate correlation with the in vivo immunizations, thus allowing for this to become a 
predictive tool saving on costs, labor, and use of animals. 
 
Nanoparticle aggregation in FBS 
Controlled release is a major appeal to the use of nanoparticles in the delivery of 
therapeutics, as it may reduce the necessity for frequent administrations reducing costs and 
patient discomfort (in the case of injectables) [25, 26]. Standard release studies are commonly 
performed with the use of media containing fetal bovine serum (FBS) to mimic the in vivo 
conditions. We aimed to tease out the kinetics of antigen release from ICMVs as well as to 
determine if antigen loss occurs through loss of lipid bilayers or complete degradation of the 
particles.  
Unfortunately, the analysis has demonstrated that while particles may remain quite stable 
in PBS, they aggregate rapidly and to a great extent in the presence of FBS or even RPMI. This 
behavior can be inferred from the markedly increased level of DiO and AF647 fluorescence and 
change in the SSC properties of the particles (Fig 4-8), whereas it was expected to exhibit a 
decrease as the particles were degraded and antigen was released. Considering that no noticeable 
aggregation or precipitation was observed visually, these large particulates may go unseen during 
standard stability and release studies, resulting in potentially skewed results. Further work with 
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other types of formulations and other approaches for aggregation determination is required to 
fully characterize and validate these methods. 
 
 
 
 
Figure 4-8. Particle stability testing.  
Particles were incubated with RPMI with or without any FBS content and demonstrate 
nanoparticle aggregation in vitro via increased SSC as well as AF647 and DiO signals. 
Individual FACS scatter plots are shown as well as the summary mean ± SD. 
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4.5. Conclusions 
 This study has focused on the development of methods necessary for analysis of surface 
antigen display of nanoparticles and membrane-based biologic vesicles. Our work allowed for 
detecting antigens presented on synthetic lipid-based nanoparticles across a dynamic range by 
utilizing fluorophore-tagged proteins or through an antibody-staining procedures. In addition, 
these methods allowed for probing of model antigen presentation on B16F10 OVA melanoma 
membrane vesicles, confirming their expression, compared to negative control CT26. Finally, we 
examined a library of antibodies with a panel of nanoparticles displaying two antigen variants. 
Utilizing the high-throughput capabilities of flow cytometry, we were able to demonstrate small 
differences within antigens, which led to more complete interpretation and understanding of 
neutralization capabilities of in vivo-generated antibody responses. With the increased use of 
nanoparticles for therapeutic use and in particular preparation of vaccine, there is a growing need 
for appropriate tools necessary for characterization and optimization. We believe that, while 
there may be a lot of room for improvement, nanoparticle flow cytometry can provide important 
information about the amount, display, and antibody-binding capabilities of antigens on particle 
surface. 
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Chapter 5: Conclusions and Future Directions 
 
 This thesis presents efficacious use of cell membranes for elicitation of immune 
responses directed against model antigen, ovalbumin, in a therapeutic cancer vaccination and 
adoptive cell transfer settings. Additionally, nanoparticle flow cytometry methodology has been 
developed for use with synthetic vaccine vehicles, but has also been shown to be applied for 
simple cell membrane vesicle analysis. Taken together, these data support previous progress and 
further advancements in the field of immunotherapy. However, there is room for improvement 
and more work is necessary in order to fully validate these results and establish working 
mechanisms for our methodology. 
 Cell lysate-based approaches to cancer immunotherapy had been studies for decades with 
limited successes in the clinic and the work demonstrated here provides a feasible therapy for 
translation and elicitation of cytotoxic T lymphocyte responses. PEG-NPs formulated using our 
protocol were able to efficiently traffic to the secondary lymphoid organs, which is the site of 
action for vaccines, and promote antigen-specific T cell expansion. We had shown that 
combination with PD-1 immune checkpoint blockade led to synergistic effects and promoted 
survival and rechallenge protection in 63% of mice compared to 13% efficacy with control 
therapies. 
 Future direction for the tumor cell membrane vaccination focuses on the use of more 
clinically relevant models outside of OVA-expressing cancers. One of the primary examples 
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would be CT26, colorectal murine tumor cell line, which expresses membrane viral antigen gp70 
with an immunogenic CD8 T cell epitope, AH-1. While still not ideal, further development in 
this model would allow for optimization and potential combination with other 
immunotherapeutic approaches such as anti-CTLA4 inhibition, which is another subset of 
immune check point blockade, working through a different mechanism [1, 2]. While PD-1 allows 
for existing T cell immunity to target and kills cancerous cells in the immunosuppressive tumor 
microenvironment, CTLA4 blockade allows for targeting of new epitopes and expansion of 
another subset of T cell clones, prompting fresh responses [3]. 
 Another aspect of targeted T cell responses focuses on tumor-associated antigens 
(TAAs), which had been extensively identified and characterized in melanoma. The use of the 
parental B16F10 cell line (lacking the model antigen OVA) would allow for studying responses 
against endogenous proteins. Interestingly, common melanoma antigens, against which 
endogenous CTLs had been identified, are often associated with the plasma or the melanosome 
membrane including gp100, NY-ESO-1, TRP2, Melan-A/MART1, and tyrosinase [4-8]. This 
observation has prompted our hypothesis, in which naturally dying or plasma membrane-
shedding tumor cells can elicit endogenous responses against TAAs, which could potentially be 
boosted through PEG-NPs or other vaccination approaches. However, the tetramer staining 
method examining peripheral blood lymphocytes we have utilized in these studies may not 
provide sufficient response detection. Further studies would focus on analysis of T cells within 
the tumor or tumor-draining lymph nodes with more sensitive techniques, such as ELISpot 
following expansion of antigen-specific T cells via peptide stimulation. These would be of 
particular importance for current work and progress being made in the field of neo-antigens [9]. 
Demonstrating endogenous responses toward membrane-associated neo-antigens may provide 
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vaccine targets for peptide-based therapies, as expanding existing cell populations rather than 
generating new clones, may yield more rapid and effective immune response, quickly halting 
further tumor progression and eliminating metastases. 
 At the same time, focus on cancer stem cell (CSC) populations and generating immune 
responses towards them would be of great benefit, as it would allow targeting the highly-
proliferative, chemotherapy-resistant, and metastasis-prone cell subset [10]. Overall debulking of 
tumors can be achieved through radiation or surgery, but further eradication of microscopic 
metastases or relapsing tumors proves quite challenging. In the past, CSC-directed DC-based 
vaccine was shown to be more efficacious at decreasing tumor burden and number of metastases 
in head and neck cancer and melanoma murine models, respectively [11]. Thus, eliciting of 
strong immune responses in situ against CSCs may provide an additional avenue for cancer 
therapy. 
 Similar direction can be utilized for the use of dendritic cell membranes for vaccination 
purposes. We had demonstrated that DC-MVs work very efficiently at expanding T cells as well 
as activating immature dendritic cells in vitro. In addition, they were capable of expanding and 
maintaining adoptively transferred antigen-specific T cells and boosting endogenous responses in 
tumor-bearing animals. While very promising, further work is necessary in order to determine 
dosing regiments necessary for optimal T cell stimulation, thus preventing over-activation, and 
characterization of differentiation into long term memory T cells. Other approaches focusing on 
the use of DC-MVs purely as adjuvants or supportive platform for T cell therapies could also be 
explored. For example, administration of DC-MVs intratumorally may provide stimulation via 
CD80/86-CD28 signaling similar to what was seen in the in vitro T cell experiments, leading to 
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breaking of the immunosuppressive microenvironment and enhancement of endogenous T cell 
responses. 
 Characterization of nanoparticles through flow cytometry provides a very attractive, 
high-throughput approach to screening and development of various therapies. Our studies 
focused primarily on the characterization of lipid-based vehicle system, NTA ICMV, and 
allowed for probing of antigenic epitopes on the surface-bound proteins with the use of 
monoclonal antibodies. These results allowed for better understanding of the humoral responses 
that were observed in vivo following immunization. We also suggest that in the future, this 
technique may be utilized as a screening and predictive tool for selection of optimal 
formulations, thus limiting the amount of empirical experiments utilizing large number of 
animals and extensive costs and labor. Additionally, we would like to focus on characterization 
of other nanoparticle-based approaches, such as simple liposomes and PLGA particles in order to 
further expand the scope of this technique. Finally, referring back to the cell membrane-based 
therapies, we had done limited characterization that has focused on the detection of antigen on 
the membrane surface. Further work could examine presence of various ligands (especially 
integrins) that had been linked in the past to localization and association with specific cell targets  
[12, 13]. In addition, functional exosomal ligands had been recently detected and reported on, 
such as FasL and PD-1L on exosomes and cell membrane vesicles shed by tumor cells resulting 
in decreased T cell function, thus providing another set of targets that could be identified via 
high-throughput flow cytometric analysis [14, 15]. 
 While the proposed studies provide an ambitious set of goals, the work demonstrated in 
this thesis had established a solid foundation for further research. Methodology developed 
through these experiments in generating and characterizing cell membrane vesicles can be 
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utilized for a variety of different studies. At the same time, the therapeutic responses that we had 
seen, add further evidence to the current notion that biologic- and immunotherapy-based 
approaches may bring in a new era of treatments against cancer, which has plagued the 
developed world for the past couple of decades. 
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Appendix: Whole-animal imaging and flow cytometric techniques for analysis of antigen-
specific CD8+ T cell responses after nanoparticle vaccination 
 
A.1 Introduction
2
 
Traditional vaccine development mainly employed the empirical approach of trial-and-
error. However, with the recent development of a wide array of biomaterials and discovery of 
molecular determinants of immune activation, it is now possible to rationally design vaccine 
formulations with biophysical and biochemical cues derived from pathogens [1, 2]. In particular, 
various particulate drug delivery platforms have been examined as vaccine carriers as they can 
be co-loaded with subunit antigens and immunostimulatory agents, protect vaccine components 
from degradation, and enhance their co-delivery to antigen presenting cells (APCs) residing in 
lymph nodes (LNs), thus maximizing immune stimulation and activation[3-5]. In this report, we 
describe the synthesis of a “pathogen-mimicking” nanoparticle system, termed interbilayer-
crosslinked multilamellar vesicles (ICMVs), which have been previously demonstrated as a 
potent vaccine platform for elicitation of robust cytotoxic T lymphocyte (CTL) and humoral 
immune responses in both systemic and mucosal tissue compartments [6-9]. Here, using ICMVs 
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as a model vaccine nanoparticle system, we describe methods for characterization of vaccine 
nano-formulations, such as particle size and zeta potential measurements, and tracking of particle 
draining to LNs utilizing confocal imaging of cryosectioned tissues[7]. In addition, we present a 
whole-animal imaging-based method of analyzing expansion of CTL responses in mice after 
adoptive transfer of luciferase-expressing antigen-specific CD8+ T cells [9, 10]. Finally, we 
describe tetramer staining of peripheral blood mononuclear cells (PBMCs) for longitudinal 
quantification of endogenous T cell responses in mice vaccinated with nanoparticles [6, 9].  
ICMVs are a lipid-based nanoparticle formulation synthesized by controlled fusion of 
simple liposomes into multilamellar structures, which are then chemically stabilized by cross-
linking maleimide-functionalized phospholipid head groups within lipid layers with dithiol 
crosslinkers [6]. Once ICMVs are synthesized, a small fraction of nanoparticles can be used to 
determine particle size and zeta potential (i.e. surface charge of particles) with a dynamic light 
scattering (DLS) system and a zeta potential analyzer. DLS measures changes in light scattering 
in particle suspension, which allows determination of the diffusion coefficient and the 
hydrodynamic size of particles [11]. Achieving consistent particle size from batch to batch 
synthesis is critical since particle size is one of the major factors influencing lymphatic draining 
of vaccine particles to draining lymph nodes (dLNs) and subsequent cellular uptake by APCs[12, 
13]. In addition, zeta potential can be obtained by measuring the particle velocity when an 
electric current is applied, which allows determination of the electrophoretic mobility of particles 
and particle surface charge [11]. Ensuring consistent zeta potential measurement of particles is 
important since surface charge of particles determines colloidal stability, which has direct impact 
on particle dispersion during storage and after in vivo administration [14, 15]. In order to track 
the particle localization to dLNs, ICMVs can be labeled with desired fluorophores including 
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lipophilic dyes and covalently-tagged antigens. Following immunization, mice can be euthanized 
at various time points, dLNs resected, cryosectioned, and analyzed with confocal microscopy. 
This technique allows for visualization of lymphatic draining of both the nanoparticle vaccine 
carriers and the antigen to dLNs. The tissue sections can additionally be stained with 
fluorescently labeled antibodies and utilized to obtain more information, such as types of cells 
associated with the antigen and formation of germinal centers as we have shown previously [7]. 
Once the particle synthesis is optimized and trafficking to the dLNs confirmed, it is 
important to validate elicitation of in vivo CTL expansion. In order to analyze elicitation of 
antigen-specific CD8+ T cells in response to nanoparticle vaccination, we have utilized a model 
antigen, ovalbumin (OVA), with OVA257-264 peptide (SIIFNEKL) immunodominant CD8+ T cell 
epitope, which allows detailed immunological analyses of antigen-specific T cell responses for 
initial vaccine development[16, 17]. In particular, to interrogate the dynamics of expansion and 
migration of antigen-specific CD8+ T cells, we have generated a double-transgenic mouse model 
by crossing firefly luciferase-expressing transgenic mice (Luc) with OT-I transgenic mice with 
T-cell receptor (TCR) specific for SIINFEKL on CD8+ T cells. From these OT-I/Luc mice, 
luciferase-expressing, OT-I CD8+ T cells can be isolated and prepared for adoptive transfer into 
naïve C57BL/6 mice. Once seeded, successful immunization with OVA-containing nanoparticles 
will result in expansion of the transferred T cells, which can be tracked by monitoring 
bioluminescence signal with an in vivo imaging system (IVIS) [9, 10]. This non-invasive whole-
body imaging technique have been used with other viral or tumor antigens in the past [18-20], 
revealing processes involved in T cell expansion in lymphoid tissues and dissemination to 
peripheral tissues in a longitudinal manner over an extended period.  
121 
 
Complementary to analysis of adoptively transferred antigen-specific CD8+ T cells, 
endogenous T cell responses post vaccination can be examined with a major histocompatibility 
complex (MHC) tetramer assay [21], in which peptide-MHC tetramer molecule, consisting of 
four fluorophore-tagged MHC-class I (MHC-I) loaded with peptide epitope, is employed to bind 
TCR and label CD8+ T cells in an antigen-specific manner. MHC tetramer assay can be 
performed either in terminal necropsy studies to identify antigen-specific CD8+ T cells in 
lymphoid and peripheral tissues or in longitudinal studies with peripheral blood mononuclear 
cells (PBMCs) obtained from serial blood draws. After staining lymphocytes with peptide-MHC 
tetramer, flow cytometry analysis is performed for detailed analyses on the phenotype of CTLs 
or quantification of their frequency among CD8+ T cells.  
 
A.2 Protocol 
All experiments described in this protocol were approved by the University Committee on Use 
and Care of Animals (UCUCA) at University of Michigan and performed according to the 
established policies and guidelines. 
 
1. Synthesis and characterization of ICMVs co-loaded with protein antigen and adjuvant 
molecules. 
1.1. Mix 1:1 molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide] (MPB) in 
chloroform, keeping the total lipid amount at 1.26 μmol per batch (i.e. 500 μg of DOPC and 630 
μg of MPB) in a 20 ml glass vial.  
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1.2. Lipophilic drugs, such as monophosphoryl lipid A (MPLA) or lipophilic dyes (e.g. DiD), 
can be added to the lipid solution at desired concentration. Thoroughly remove the organic 
solvent by purging with extra dry nitrogen gas or by placing the samples under vacuum 
overnight. 
1.3. Hydrate the lipid film using 200 μl of 10 mM bis-trip propane (BTP, pH 7.0) containing 
water-soluble drugs (e.g. protein antigens). Vortex for 10 sec every 10 min for 1 hr at RT. 
1.4. Transfer the contents from the glass vial into a 1.5 ml microcentrifuge tube, place samples in 
an ice-water bath, and sonicate continuously for 5 min using 40% intensity setting on a 125 
W/20 kHz probe-tip sonicator.  
1.5. Add 4 μl of 150 mM dithiothreitol (DTT) to each batch (working concentration 2.4 mM), 
vortex, and briefly centrifuge using a tabletop microcentrifuge.  
1.6. Add 40 μl of 200 mM CaCl2 and mix with the pipette (working concentration 33 mM). 
Incubate samples at 37 °C for 1 hr to allow crosslinking of MPB-containing lipid layers with 
DTT. 
1.7. Centrifuge samples at 20,000 x g for 15 min, remove the supernatant, and resuspend in 200 
μl of ddiH2O. 
1.8. Repeat step 1.7 and centrifuge again after the second ddiH2O wash. 
1.9. Prepare 10 mg/ml of 2 kDa polyethylene glycol-thiol (PEG-SH) in ddiH2O. Resuspend each 
ICMV sample in 100 μl of PEG-SH solution and incubate at 37 °C for 30 min. 
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1.10. Perform two ddiH2O washes (step 1.7) and resuspend the final ICMV pellet in PBS and 
store at 4 °C. Prior to use, mix the ICMV suspension, as particles may settle to the bottom after 
prolonged storage.  
1.11. For characterization of particles, remove a small aliquot (~10%) of ICMVs from each batch 
and dilute individually in a total volume of 1 ml of ddiH2O. Place a single sample in a zetasizer 
cell and measure particle size, polydispersity index, and zeta potential of the samples using 
dynamic light scattering and zeta potential measuring system (according to manufacturer’s 
protocol).  
 
2. Examination of lymph node draining of fluorescence-tagged ICMVs with confocal 
microscopy 
2.1. Preparation of ICMVs loaded with fluorophore-tagged antigen and lipophilic 
fluorescent dye 
2.1.1. Prepare fluorophore-tagged protein, such as ovalbumin reacted with Alexa Fluor 555-
succinimidyl ester according to the manufacturer’s instruction. 
2.1.2 To prepare ICMVs tagged with fluorophore in the lipid shell, add lipophilic fluorescent 
dye, (e.g. 1, 1′ Dioctadecyl 3,3,3′,3′ Tetramethylindodicarbocyanine, (DiD)) during preparation 
of the lipid film (Step 1.2) at 0.05% molar lipid amount. For lipid film hydration (Step 1.3), use 
buffer containing fluorophore-tagged antigen, and complete ICMV synthesis as outlined in steps 
1.4.-1.11. 
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2.2. Subcutaneous administration of nanoparticles at tail base 
2.2.1. Anesthetize mouse using a controlled flow vaporizer equipped with an induction chamber 
utilizing 3% isoflurane and 1.5 L/min of oxygen flow according to an IACUC approved animal 
protocol. Once the mouse is unconscious, perform the following steps quickly prior to the 
anesthesia wearing off to allow optimal access to the site of the injection and minimize 
discomfort to the animal. Alternatively, use a proper fitting nose cone to maintain anesthesia. If 
mice are anesthetized for longer than 5 min, apply eye lube necessary to minimize irritation after 
the procedure. 
2.2.2. Spray the base of the tail with 70% ethanol to sterilize and wet the fur. Part the wet hair to 
expose a small patch of visible skin, which can be used to visualize the needle under the skin. 
2.2.3. Prepare particle injection suspension containing desired amount of antigen and adjuvant 
per 100 μl of vaccination dose in PBS (e.g. 10 μg OVA and 0.3 μg MPLA per 100 μl of injection 
dose has been used in the past[6, 9]).  
2.2.4. Draw the particle suspension into a syringe with a 27-29G needle and insert the needle at 
the base of the tail with the bevel facing up (assuring to avoid the tail vein) and inject 50 μl of the 
particle suspension[22].  
2.2.5. Wait a few seconds for pressure to equalize to prevent excessive back-flow and pull the 
needle out. Repeat the injection on the other side of the tail base to target both draining inguinal 
LNs. 
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2.3. Preparation of lymph node cryosections and examination with confocal microscopy.  
2.3.1. Euthanize the mouse with CO2 asphyxiation, followed by induced pneumothorax 
according to an IACUC approved animal protocol. Extract inguinal LNs according to protocol 
demonstrated in Bedoya, et al.[23] and wash out the blood by placing the tissues in 1 ml of 4°C 
PBS. 
2.3.2. Absorb the PBS from the tissues with Kimwipes and place tissue in tissue cryomolds (10 x 
10 x 5 mm) pre-filled to the top with OCT freezing medium[24]. Snap freeze the tissue block in 
liquid nitrogen for 30 seconds. Alternatively, place tissue block on dry ice for 30 min. Store 
frozen tissue in -80 °C freezer. 
2.3.3. Cut tissue sections 5-10 μm thick in a cryostat set at -20 °C[24]. 
2.3.4. If necessary, perform immunofluorescence labeling, and examine the tissue with confocal 
microscopy as previously demonstrated[24]. 
 
3. Monitoring expansion of antigen-specific, luciferase-expressing CD8+ T cells after 
nanoparticle vaccination with whole animal imaging. 
3.1. Isolation of OVA257-264-specific, luciferase-expressing CD8+ T cells from OT-I/Luc 
transgenic mice 
3.1.1. Euthanize an OT-I/Luc transgenic mouse with CO2 asphyxiation and induce a 
pneumothorax according to an IACUC approved animal protocol. Harvest the spleen in a sterile 
126 
 
manner by accessing the peritoneal cavity and carefully detaching the tissue from the 
pancreas[23], and place in 5 ml of 4°C PBS + 2% FBS for transfer to tissue culture hood.  
3.1.2. Place the spleen on a 70 μm nylon strainer over a 50 ml conical centrifuge tube (up to 3 
spleens at a time). Using a plunger from a 3 ml syringe, grind the cells through the strainer. 
3.1.3. Wash the plunger and the strainer with PBS + 2% FBS and discard. Bring the total volume 
to 10 ml/spleen in the 50 ml tube, take a small sample of the cell suspension to count with 
hemacytometer, and centrifuge for 10 minutes at 300 x g.  
3.1.4. Using a commercially available magnetic negative selection kit, isolate the CD8+ T cell 
population by following the manufacturer’s instructions.  
3.1.5. After washing cells with PBS, count the number of isolated CD8+ T cells. To assess purity 
of isolated CD8+ T cells, incubate ~20,000-30,000 cells in 20 μl of mouse CD16/32 antibody 
(0.025 mg/ml) for 10 minutes, then add 20 μl αCD8-APC antibody (0.005 mg/ml) and incubate 
for 30 minutes. Perform all incubations at 4 °C in PBS + 1% w/v BSA. Perform flow cytometric 
analysis[25]. 
 
3.2. Adoptive transfer of isolated CD8+ T cells and visualization of their expansion post 
vaccination 
3.2.1. Perform adoptive transfer of isolated OT-I/Luc CD8+ T cells into naïve C57BL/6 mice by 
administering 1-10 × 10
5
 cells in a 200 μl volume of PBS via intravenous tail vein injection[22] 
(day -1). Considering that fur and black skin patches in C57BL/6 mice may interfere with the 
bioluminescent signal, shaved albino C57BL/6 mice are ideal for these studies. 
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3.2.2. After one day (day 0), administer the vaccine as described previously (section 2.2).  
 
3.2.3. Administer 150 mg luciferin per kg mouse body weight intraperitoneally in 300 μl volume 
in PBS. After 10 minutes, anesthetize the mice with isoflurane (as in step 2.2.1) and visualize 
OT-I/Luc CD8+ T cells by acquiring bioluminescence signal for 5-10 min with a whole animal 
imaging system (IVIS; refer to Wilson, et al.[26] for detailed instruction). Repeat as necessary 
for longitudinal studies. 
 
4. Peptide-MHC tetramer staining of PBMCs for analysis of antigen-specific CD8+ T cells.  
Note: The following protocol procedure can be performed using either C57BL/6 mice adoptively 
transferred with OT-I/Luc CD8+ T cells or C57BL/6 mice without the adoptive transfer. 
4.1. On a desire time point after vaccination, collect approximately 100 μl of blood from mice 
via submandibular bleeding technique[27] into a tube coated with K2EDTA and invert several 
times to prevent clotting. 
 4.2. Transfer 100 μl of blood to a microcentrifuge tube, add 1 ml of ACK lysis buffer, and 
incubate for 2 to 3 minutes in order to remove red blood cells (RBCs). Centrifuge samples for 5 
minutes at 1500 x g and remove the supernatant. If the pellet still appears red (indicating 
incomplete removal of RBCs), repeat the lysis step with a brief incubation (< 1 min) of ACK 
lysis buffer. 
4.3. Wash the remaining PBMCs with 1 ml of FACS buffer (PBS + 1% w/v BSA) and centrifuge 
at 1500 x g for 5 minutes. 
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4.4. Aspirate the supernatant and resuspend the sample in 20 μl of mouse CD16/32 antibody 
(0.025 mg/ml) to block nonspecific and FcR-mediated antibody binding. Incubate for 10 minutes 
at room temperature. 
4.5. Transfer cells from microcentrifuge tubes into 4 ml round bottom FACS tubes. Add 20 μl of 
H-2K
b
 OVA Tetramer-SIINFEKL-PE solution according to manufacturer’s specifications to 
each sample and incubate for 30 minutes on ice. 
4.6. Prepare the antibody cocktail (e.g. αCD8-APC, αCD44-FITC, and αCD62L-PECy7 
antibodies (0.005, 0.005, and 0.002 mg/ml concentration, respectively)). Add 20 μl to each 
experimental sample, and incubate for 20 minutes on ice. Prepare single fluorophore controls by 
labeling cells with each fluorophore-tagged tetramer or antibody at the concentration indicated 
above.  
4.7. Wash 2 times with FACS buffer and resuspend the final pellet in FACS buffer containing 2 
μg/ml of DAPI. The cells are now ready for flow cytometry analysis (details and examples can 
be found in Scheffold, et al.[25]). 
 
A.3 Representative Results  
The steps involved in the synthesis of ICMVs are illustrated in Figure 1[6]. Briefly, a 
lipid film containing any lipophilic drugs or fluorescent dyes is hydrated in the presence of 
hydrophilic drugs. Divalent cations, such as Ca
2+
, are added to drive fusion of anionic liposomes 
into multilamellar vesicles. Dithiol crosslinker, such as DTT, is added to “staple” maleimide-
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functionalized lipids on apposing lipid layers, and finally remaining external maleimide groups 
are quenched in a reaction with thiolated-PEG moieties. A small fraction of each batch can be 
readily subjected to quality control measurements by determining particle size, polydispersity 
index, and zeta potential with dynamic light scattering and zeta potential analyzer. The resulting 
particles are relatively homogenous with an average size of 130 ± 24 nm, polydispersity index of 
0.22 ± 0.022, and zeta potential of -54 ± 2.6 mV for OVA-encapsulating particles (Fig.  A-1B 
and A-1C). Typical yield of particles, measured in dry weight of particles, is ~ 50%[6].  
Using the protocol described above, ICMVs can be co-loaded with fluorophore-tagged 
protein antigen and fluorescent lipophilic dye, allowing visualization of antigen and nanoparticle 
delivery in vivo. To compare the patterns of antigen delivery in soluble form versus in ICMVs, 
C57BL/6 mice were administered s.c. at tail base with 100 μg of AlexaFluor555-tagged OVA 
either in soluble or DiD-labeled ICMV formulations, and draining inguinal LNs were excised on 
various time points for preparation of dLN tissue sections. Visualization with confocal 
microscopy indicated that soluble antigen quickly reached the dLNs within 4 h, but was also 
cleared very rapidly with 24 h (Fig. A-2)[7]. In contrast, OVA-loaded ICMVs were detected at 
the periphery of dLNs by 24 h, with continued accumulation as examined on day 4, depositing a 
large amount of OVA-ICMVs in dLNs (Fig. A-2). Confocal micrographs also showed co-
localization of AlexaFluor555-tagged OVA and DiD-labeled ICMVs within dLNs, suggesting 
that ICMVs permit stable co-delivery of protein antigen and other immunostimulatory agents 
encapsulated within ICMVs[7].   
Isolation of CD8+ T cells from OT-I/Luc transgenic mouse can be readily performed 
with the commercially available magnetic negative selection kit, yielding ~ 8-12 x 10
6
 cells per a 
mouse spleen. Figure A-3 shows C57BL/6 mice adoptively transferred with 5 x 10
5
 OT-I/Luc 
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CD8+ T cells on day -1, and immunized on day 0 with s.c. administration of 10 μg OVA and 0.3 
μg MPLA either in soluble or ICMV formulations. Bioluminescence imaging with IVIS 
performed on day 0 prior to vaccination showed minimal OT-I/Luc signal. However, by day 4, 
mice immunized with OVA/MPLA-ICMVs had robust bioluminescence signal within inguinal 
LNs, which are LNs draining the tail base region[28]. In contrast, mice immunized with the 
soluble form of the vaccine showed much reduced expansion of OT-I/Luc CD8+ T cells within 
inguinal dLNs.  
Using OVA as a model antigen allows monitoring of expansion of endogenous CD8+ T 
cells specific to immunodominant OVA257-264 peptide (SIINFEKL). For an example, C57BL/6 
mice were immunized on days 0, 21, and 35 with s.c. administration of 10 g OVA and 0.3 g 
MPLA in either ICMVs or soluble form, and frequencies of SIINFEKL-specific CD8+ T cells 
among CD8+ T cells in PBMCs were determined by flow cytometric analysis of PBMCs stained 
with SIINFEKL-H-2K
b
 tetramer-PE. Figure A-4A shows representative flow cytometry scatter 
plots of SIINFEKL-H-2K
b
 tetramer
+
 cells among CD8+ T cells in PBMCs on day 41[6]. Weekly 
monitoring of PBMCs shown in Figure A-4B indicated that soluble OVA vaccine elicited 
minimal expansion of antigen-specific CD8+ T cell, whereas ICMV vaccination elicited 
significantly stronger CD8
+
 T cell responses, achieving a peak 28% SIINFEKL-tetramer
+
 T cells 
in the CD8
+
 T cell population by d 41[6]. 
 
A.4 Discussion  
The protocol provided in this article describes the synthesis and characterization of a new 
lipid-based nanoparticle system, termed ICMVs, and provides the process of validating 
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effectiveness of nanoparticle-based vaccine formulations to induce antigen-specific CD8+ T cell 
responses. ICMV synthesis is completed in all aqueous condition, which is a major advantage 
compared with other commonly used polymeric nanoparticle systems (e.g. poly(lactide-co-
glycolide) acid particles), which typically require organic solvents for preparation, often 
resulting in loss of antigenicity in protein antigens[29, 30]. In addition, ICMVs benefit from 
extensive stability and potential of encapsulating hydrophobic and hydrophilic molecules[6], 
thus permitting co-delivery of antigens and adjuvants targeted to the same intracellular 
compartment within APCs[31, 32]. Using ICMVs as a model vaccine nanoparticle, here we have 
outlined the procedures for (1) nanoparticle synthesis and characterization, (2) validation of 
nanoparticle drainage to dLNs, and examination of elicitation of antigen-specific CD8+ T cell 
responses using (3) non-invasive bioluminescence imaging technique and (4) peptide-MHC 
tetramer staining assay on PBMCs.  
It is critical to ensure uniformity in nanoparticle synthesis from batch to batch, especially 
for particle size and surface charge as they can greatly affect lymphatic draining and uptake by 
APCs upon in vivo administration. DLS and zeta potential analyzer provide quick methods of 
quality check on particle size and surface charge. For more detailed analyses on morphology of 
individual particles, these techniques can be complemented with high-resolution electron 
microscopy, such as scanning electron microscopy (SEM) or transmission electron microscopy 
(TEM), which are generally compatible with solid core nanostructures that are resistant to 
dehydration during sample preparation. For hollow core nanomaterials, such as ICMVs based on 
lipid vesicles, cryo-electron microscopy (cryo-EM) that preserves morphology of “soft” particles 
in vitrified aqueous layer is more suitable[6, 33, 34].  
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Particles smaller than 100 nm are generally believed to effectively enter the lymphatic 
vessels and traffic to dLNs[13], whereas larger microparticles require active transport by tissue-
resident DCs[35]. In our hands, ICMVs with the hydrodynamic size ranging from 150-250 nm 
efficiently localized and persisted in the dLN, resulting in extensive CTL and humoral 
responses[6, 7]. These studies have utilized fluorophore-tagged nanoparticles and protein 
antigens to delineate their localization and distribution patterns in dLNs. Confocal microscopy of 
cryosectioned dLNs allows for additional immunofluorescence histochemistry for identification 
of LN structures and cells interacting with the formulation components. This technique can be 
performed in parallel with flow cytometry analyses of cells harvested from dLNs to delineate the 
subsets of APCs responsible for particle uptake [7, 9] or with whole-animal imaging to quantitate 
vaccine delivery from injection site to dLNs [36, 37], provided that the fluorescent signals are 
strong and tissue autofluorescence does not interfere with the signals.  
Effective immunization requires robust activation and expansion of antigen-specific 
cytotoxic T cells, which can be tracked by whole-body bioluminescence imaging after adoptive 
transfer of bioluminescent, antigen-specific transgenic T cells, followed by vaccination. The 
added benefit of this method is repeated visualization of CTL trafficking in the same animals for 
an extended period, potentially reducing the number of animals required for immunological 
analyses and avoiding the use of laborious cell isolation procedures. Using this imaging 
technique, we have recently demonstrated that pulmonary administration of ICMVs co-loaded 
with protein antigen and an immunostimulatory agent led to potent elicitation of antigen-specific 
CD8+ T cells in the lung and mediastinal LNs and subsequent dissemination of CTLs to distal 
mucosal tissues, including Peyer’s patches, cecum, and vaginal tract[9]. Flow cytometric 
analyses showed that these newly expanded CD8+ T cells were imprinted with a “mucosal-
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homing” phenotype characterized by α4β7
+
 integrin expression and mediated protective immune 
responses against mucosal viral challenge[9]. The whole-animal imaging of bioluminescent 
CD8+ T cells was also recently utilized by Hailemicheal, et. al, who demonstrated that tumor 
antigen peptide formulated into incomplete Freund’s adjuvant (IFA, oil-in-water emulsion) 
resulted in sequestration of T cells at the site of the injection with vaccine “depot” away from the 
tumor masses, leading to T cell dysfunction and deletion[38].  
Tetramer staining has been used extensively in the past to quantify the level of 
endogenous CTL responses resulting from various vaccine formulations [21]. This technique is 
also relevant and commonly utilized in early human cancer immunotherapy clinical trials to 
confirm CTL responses to specific tumor-associated antigens [39, 40]. Compatibility of this 
method with flow cytometry allows determination of antigen-specific T cells with memory 
markers (CD44, CD62L, CD127, Bcl-2, and KLRG-1) to distinguish effector, central memory, 
and effector memory cells among the tetramer+ T cells[41] or long-lasting tissue resident CTLs 
[42, 43]. However, tetramer staining assay provides only the initial assessment of CTL responses 
since highly-expanded antigen-specific T cells may exhibit signs of immune exhaustion [44, 45]. 
Functional evaluation of CTL responses can be performed by examining cytokine release with 
enzyme linked immunospot (ELISpot )[46] or intracellular cytokine staining[47] after ex vivo 
stimulation of lymphocytes with minimal epitopes as well as by measuring the intracellular 
levels of perforin and granzyme B [48] and extracellular expression of CD107a and CD107b 
upon degranulation [49]. In addition, cytolytic function of CTLs can be directly assessed with 
CTL cytotoxicity assay performed in vitro or in vivo [50-52].  
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Figure A-1: Synthesis and characterization of interbilayer-crosslinked multilamellar 
vesicles (ICMVs).  
(A) ICMVs are synthesized in the following 4 steps; (i) anionic, maleimide-functionalized 
liposomes are prepared from dried lipid films; (ii) divalent cations are added to induce fusion of 
liposomes and the formation of multilamellar vesicles; (iii) membrane-permeable dithiols are 
added, which crosslink maleimide-lipids on apposed lipid bilayers in the vesicle walls; and (iv) 
the resulting lipid particles are PEGylated with thiol-terminated PEG. (B) Representative particle 
distribution as analyzed by DLS is shown. (C) Average hydrodynamic size, polydispersity index, 
and zeta potential of ICMVs co-loaded with OVA and MPLA are shown. Panel (A) has been 
modified from Moon et al.
[6]
 with permission.  
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Figure A-2. Analysis of antigen draining to lymph nodes with confocal microscopy.  
C57Bl/6 mice were immunized with 100 μg fluorophore-conjugated OVA (shown in red) and 5 
μg MPLA either in solution or ICMVs (shown in blue). Draining inguinal lymph nodes were 
excised at indicated time points, cryosectioned, and imaged with confocal microscopy. 
Representative confocal micrographs are shown. Pink signals indicate co-localization of OVA 
and ICMVs. This figure has been modified from Moon et al.[7] with permission.  
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Figure A-3. Monitoring T cell expansion after vaccination.  
C57Bl/6 albino mice were adoptively transferred i.v. with 5 x 10
5 
Luc
+
 OT-I CD8
+
 T cells on day 
-1. On day 0, the animals were administered with 10 μg OVA and 0.1 μg MPLA either as soluble 
or ICMV formulations. The animals were anesthetized with isoflurane and administered with 
luciferin (150 mg/kg, 300 μl injected i.p.), and bioluminescence signal from Luc+OT-1 CD8+ T 
cells was acquired with IVIS. 
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Figure A-4. Expansion of endogenous OVA-specific CD8+ T cells after ICMV vaccination. 
C57Bl/6 mice were immunized with 10 μg OVA and 0.1 μg MPLA either in solution or ICMVs 
on days 0, 21, and 35 (arrows). Frequency of OVA-specific T cells among peripheral blood 
mononuclear cells was assessed over time by flow cytometric analysis of SIINFEKL-MHC-I 
tetramer
+
 CD8+ T cells. (A) Representative flow cytometry scatter plots from individual mice at 
day 41 are shown, and (B) overall kinetics of T cell expansion and contraction is shown. This 
figure has been modified from Moon et al.[6] with permission. 
 
 
 
